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Key Terms in Palliative Care and Pain Treatment 
 
Essential medicine: A medicine included in the World Health Organization’s Model List of 
Essential Medicines.  
Palliative care: Health care that aims to improve the quality of life of people facing life-
limiting illnesses, through pain and symptom relief, and through psychosocial support for 
patients and their families. Palliative care can be delivered in tandem with curative 
treatment but its purpose is to care, not to cure. 
Life-limiting illness: A broad range of conditions in which painful or distressing symptoms 
occur; although there may also be periods of healthy activity, there is usually at least a 
possibility of premature death. 
Hospice: A specialist medical facility that provides palliative care. Hospices can be 
residential or outpatient facilities.  
Chronic pain: As used in this report, pain that occurs over weeks, months, or years, rather 
than a few hours or a few days. Because of its duration, moderate to severe chronic pain 
should be treated with oral opioids rather than repeated injections, especially for children 
and people who are emaciated by diseases such as cancer and HIV/AIDS. 
Opioid: Drugs derived from the opium poppy and similar synthetic drugs. All strong pain 
medicines, including morphine and pethidine, are opioids. Weaker opioids include 
codeine and tramadol. 
Morphine: A strong opioid medicine, the gold standard for treatment of moderate to 
severe pain. Morphine is considered an essential medicine by the World Health 
Organization in its injectable, tablet, and oral solution formulations. Oral solution mixed 
from morphine powder is the cheapest formulation. 
Basic pain medicines: Non-opioid pain medicines suitable for mild pain. These include 
paracetamol (also known as acetaminophen), aspirin, diclofenac, and ibuprofen. 
Opioid dependence: Physical dependence experienced by a patient treated with opioids 
over time, such that withdrawal symptoms occur if the opioid is stopped abruptly. 
Physical dependence is treated by gradually reducing the opioid dose. It is distinct from 
addiction, a pattern of behaviors including compulsive use of drugs despite harm, which 
is uncommon in patients receiving opioid pain treatment. 
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Primary healthcare facility: A medical facility that a patient will usually attend first in a 
non-emergency situation, such as a clinic or healthcare center. Many patients globally 
only have access to primary-level health care.  
Tertiary hospital: A large hospital at the peak of a hierarchy of hospitals. A tertiary 
hospital provides all of the major medical services available in a country and admits 
patients referred from smaller hospitals that provide fewer services.  
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Summary 
 
Every year, tens of millions of people around the world with life-threatening illnesses suffer 
unnecessarily from severe pain and other debilitating symptoms because they lack access to 
palliative care, an inexpensive health service that aims to improve the quality of life of 
people with serious health conditions. As Human Rights Watch has documented, their 
suffering is often so intense they would rather die than live with their pain. 
 
Although the World Health Organization (WHO) considers palliative care an integral 
component of cancer care and has urged countries to improve its availability, too often 
palliative care continues to be the neglected child of the health care family, receiving low 
priority from health policy makers and health care professionals and almost no funding. This 
is despite the fact that experts estimate that 60 percent of those who die each year in the 
developing world—a staggering 33 million people—need palliative care.1 In part, this is 
because most cancer patients in developing countries are diagnosed when they have 
advanced disease and cannot be cured, so the only treatment option is palliative care. 
 
Fifty years ago this year, the world community adopted the 1961 Single Convention on 
Narcotic Drugs, which stated that narcotic drugs are “indispensible for the relief of pain and 
suffering,” a core function of palliative care. It also instructed states to make adequate 
provision to ensure their availability. Yet, today these essential pain relieving drugs continue 
to be so poorly available in most of the world that WHO estimates that each year tens of 
millions of people suffer untreated moderate to severe pain, including 5.5 million terminal 
cancer patients and 1 million patients in the last phases of HIV/AIDS.2 
 
In 2009 and 2010 Human Rights Watch surveyed palliative care experts in 40 countries to map 
the barriers that impede the availability of palliative care and pain treatment worldwide. We 
asked them about the situation in their country in three areas that WHO has said are critical to 
the development of palliative care: health policy, education of healthcare workers, and drug 
availability. We also analyzed publicly available data from all countries on consumption of 
opioid medications that can be used to treat chronic pain and compared them to cancer and 
AIDS mortality data to assess how well the need for pain treatment is met. 
                                                          
1 J. Stjernsward & D. Clark, Palliative Medicine: A Global Perspective, in Derek Doyle et al., eds., Oxford Textbook of Palliative 
Medicine (Oxford: Oxford University Press, 3rd ed., 2003) pp. 1199-1222. 
2 “Briefing Note: Access to Controlled Medicines Program,” World Health Organisation Briefing Note, February 2009, 
http://www.who.int/medicines/areas/quality_safety/ACMP_BrNoteGenrl_EN_Feb09.pdf (accessed August 6, 2010). 
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We found enormous unmet need for pain treatment. Fourteen countries reported no 
consumption of opioid pain medicines between 2006 and 2008, meaning that there are no 
medicines to treat moderate to severe pain available through legitimate medical channels in 
those countries. In a further eight countries that do not report their consumption of opioids, 
the situation is likely similar, as governments participating in the international drug control 
regime will not export opioids to those that do not. Thirteen other countries do not consume 
enough opioids to treat even one percent of their terminal cancer and HIV/AIDS patients. 
These countries are concentrated in Sub-Saharan Africa, but are also found in Asia, the 
Middle East and North Africa, and Central America.  
 
Some of the world’s most populous countries have very poor availability of opioids for pain 
relief. Consequently, in each of China, India, Indonesia, Nigeria, Russia, and South Africa, at 
least 100,000 people die from cancer or HIV/AIDS each year without access to adequate 
pain treatment. The combined suffering due to lack of opioid pain medicines worldwide is 
staggering. Our calculations confirm that more than 3.5 million terminal cancer and HIV/AIDS 
patients die each year without access to adequate pain treatment, a very conservative 
estimate that assumes that all opioids are used to treat this patient group. It should be 
considered merely an indicator of the enormous unmet need for pain treatment. In reality, 
the limited opioids that are available are used to treat patients suffering pain from other 
causes too. So the real number of terminal cancer and HIV/AIDS patients with untreated pain 
must be higher, and many other patients with non-terminal cancer, HIV/AIDS, and with other 
diseases are also suffering untreated pain.  
  
In many of the 40 countries surveyed we found multiple barriers to palliative care in each of 
the three areas. Only 11 of the countries surveyed have a national palliative care policy, 
despite WHO’s recommendation that countries put in place such policies. Most of the 
countries surveyed have inadequate opportunities for medical education in pain 
management or palliative care and in four of the countries surveyed–Cameroon, Ethiopia, 
Jordan, and Tanzania–no such education is available at all.  
 
Thirty-three of the forty countries surveyed impose some kind of restrictive regulation on 
morphine prescribing that is not required by the international drug conventions. Thirty-one 
of the countries require that a special prescription form be used to prescribe morphine, and 
fourteen require doctors to have a special license to prescribe morphine. Although WHO has 
recommended that countries consider allowing nurses to prescribe morphine in order to 
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improve accessibility to this essential medicine, only three countries (the United States and 
Uganda) do so.3 
 
Our survey also identified some bright spots. Countries like Colombia, Jordan, Romania, 
Uganda, and Vietnam have undertaken comprehensive reform programs to improve access 
to palliative care. In these countries, leaders from the medical community have worked with 
domestic and international NGOs and their own governments to assess what barriers are 
preventing patients from accessing pain treatment and to address these barriers through 
policy development, law reform, and improving medical education and drug supply.  
 
Governments have an obligation to address the widespread and unnecessary suffering 
caused by the poor availability of palliative care worldwide. Under international human 
rights law, governments must ensure equal access to the right to health and take reasonable 
steps to protect all against inhuman and degrading treatment. This should mean that health 
policies address the needs of people who require palliative care services; that healthcare 
workers have at least basic palliative care knowledge and skills; that medications like 
morphine are available throughout the country; and that drug regulations do not impede the 
ability of patients facing severe pain to get appropriate treatment. Failure to take such steps 
will likely result in a violation of the right to health. In some cases, failure to ensure patients 
have access to treatment for severe pain will also result in violation of the prohibition of 
cruel, inhuman, and degrading treatment. 
 
The international community should address the poor availability of palliative care with 
urgency. Although WHO has urged countries to ensure the availability of palliative care, its 
governing body, the World Health Assembly, has largely been silent on the issue, despite the 
large numbers of people who require palliative care and the great suffering lack of palliative 
care causes. It needs to urgently show leadership and instruct its members to take effective 
steps to improve palliative care. 
 
In recent years, the UN drug policy bodies, the Commission on Narcotic Drugs (CND), the UN 
Office on Drugs and Crime (UNODC), and the International Narcotics Control Board (INCB), 
have significantly increased the amount of attention that they pay to the availability of 
strong pain medications. In 2010 CND adopted a resolution on the issue, and UNODC 
discussed it prominently in the World Drug Report, its flagship publication. In 2011 the INCB 
published a special supplement to its Annual Report devoted to this issue. Improving access 
                                                          
3 In the United States, most, but not all states, allow nurses to prescribe morphine. In Cameroon nurses with training in 
palliative care prescribe morphine, but it is not clear whether the law authorizes this.  
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to essential medicines should be one aspect of a greater emphasis on promoting human 
rights within the UN drug policy bodies’ work. To mark the 50th anniversary of the 1961 Single 
Convention on Narcotic Drugs, these UN bodies should build on this momentum and 
develop concrete plans to implement the CND resolution and the INCB’s recommendation.  
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I. Background: Palliative Care and Pain Treatment 
 
The Need for Palliative Care and Pain Treatment  
Palliative care is a compassionate response to the suffering of patients with life-limiting 
illnesses like cancer or HIV/AIDS. It seeks to improve the quality of life of patients and their 
families facing life-limiting illness. Unlike curative health care, its purpose is not to cure a 
patient or extend his or her life, but rather to prevent and relieve pain and other physical, 
psychosocial, and spiritual problems. As Dame Cicely Saunders, founder of the first modern 
hospice and a lifelong advocate for palliative care, is widely reported to have said, palliative 
care is about “adding life to the days, not days to the life.”  
 
The World Health Organization recognizes palliative care to be an integral part of health care 
for cancer, HIV/AIDS, and various other health conditions, that should be available to those 
who need it.4 While palliative care is often associated with cancer, a much wider circle of 
patients with health conditions that limit their ability to live a normal life can benefit from it, 
including those with dementia, heart, liver or renal disease, or chronic and debilitating 
injuries. Palliative care is often provided alongside curative care services. 
 
WHO has emphasized that palliative care is particularly important in developing countries, 
where the burden of HIV/AIDS is greatest, treatment is not universally available, and many 
patients with cancer seek medical attention only when the disease is in an advanced stage, 
beyond cure but causing severe pain.5 While palliative care providers may offer inpatient 
services at hospices or hospitals, their focus is frequently on home-based care for people 
who are terminally ill or have life-limiting conditions, thus reaching people who otherwise 
might not have any access to healthcare services, including pain management. WHO has 
urged countries with limited resources to focus on developing home-based palliative care 
services, which can be provided by a visiting nurse or community health worker under the 
supervision of a doctor, making them very cost-effective.6  
 
                                                          
4 WHO, “National Cancer Control Programmes: Policies and Managerial Guidelines, second edition,” pp. 86-87. 
5 World Health Organization, “National Cancer Control Programs: Policies and Managerial Guidelines,” 2002, 
http://www.who.int/cancer/media/en/408.pdf (accessed August 6, 2010) pp. 85-86.  
6 Ibid., pp. 85, 91. 
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Moderate to severe pain is a common symptom of cancer and HIV/AIDS, as well as of many 
other health conditions.7 A recent review of pain studies in cancer patients found that more 
than 50 percent experience pain,8 and research consistently finds that 60 to 90 percent of 
patients with advanced cancer experience moderate to severe pain.9  
 
Although no population-based studies of AIDS-related pain have been published, multiple 
studies report that 60 to 80 percent of patients in the last phases of illness experience 
significant pain.10 Increasing availability of antiretroviral treatment (ART) in middle and low-
income countries is prolonging the lives of many people with HIV. While people receiving 
ART generally have less pain than people who are not able to obtain it, many continue to 
experience pain symptoms.11 ART can itself be a cause of pain, especially neuropathic pain 
caused by damaged nerves.12  
 
The Consequences of Untreated Pain and Lack of Palliative Care 
Moderate to severe pain, as well as other physical and psychosocial symptoms, have a 
profound impact on quality of life. Pain can lead to reduced mobility and consequent loss of 
strength; compromise the immune system; and interfere with a person’s ability to eat, 
                                                          
7 Pain is also a symptom in various other diseases and chronic conditions and acute pain is often a side effect of medical 
procedures. This paper, however, focuses primarily on chronic pain. 
8 M. van den Beuken-van Everdingen et al., “Prevalence of Pain in Patients with Cancer: A Systematic Review of the Past 40 
Years,” Annals of Oncology, vol. 18, no. 9 (2007) pp. 1437-1499. 
9 Charles S. Cleeland et al., “Multidimensional Measurement of Cancer Pain: Comparisons of U.S. and Vietnamese Patients,” 
Journal of Pain and Symptom Management vol. 3, no. 1 (1988); Charles S. Cleeland et al., “Dimensions of the Impact of Cancer 
Pain in a Four Country Sample: New Information from Multidimensional Scaling,” Pain, vol. 67, no. 2-3 (1996) pp. 267-73; 
Randall L. Daut & Charles S. Cleeland, “The Prevalence and Severity of Pain in Cancer,” Cancer vol. 50, no. 9 (1982) p. 1913; 
Kathleen M. Foley, Pain Syndromes in Patients with Cancer, in Kathleen M. Foley et al., eds., Advances in Pain Research and 
Therapy (1979) pp. 59-75;Kathleen M. Foley, “Pain Assessment and Cancer Pain Syndromes,” in Derek Doyle, Geoffrey W.C. 
Hanks and Neil MacDonald, Oxford Textbook of Palliative Medicine (Oxford: Oxford University Press, 2nd ed., 1999), pp. 310-
331; J. Stjernsward & D. Clark, Palliative Medicine: A Global Perspective, in Derek Doyle et al., eds., Oxford Textbook of 
Palliative Medicine (Oxford: Oxford University Press, 3rd ed., 2003) pp. 1199-1222. 
10 K. Green, Evaluating the Delivery of HIV Palliative Care Services in Out-Patient Clinics in Viet Nam, Upgrading Document, London 
School of Hygiene and Tropical Medicine (2008); Kathleen M. Foley et al., “Pain Control for People with Cancer and AIDS,” in Dean T 
Jamison et al., Disease Control Priorities in Developing Countries (Washington: World Bank Publications, 2nd ed. 2003), pp. 981-994; 
Francois Larue et al., “Underestimation and Under-Treatment of Pain in HIV Disease: A Multicentre Study,” British Medical Journal, 
vol. 314 (1997) http://www.bmj.com/cgi/content/full/314/7073/23 (accessed August 6, 2010) p. 23; J. Schofferman & R. Brody, Pain 
in Far Advanced AIDS, in K. M. Foley et al., eds., Advances in Pain Research and Therapy (1990) pp. 379-386; E. J. Singer et al., 
“Painful Symptoms Reported by Ambulatory HIV-Infected Men in a Longitudinal Study," Pain, vol. 54 (1993) pp. 15-19. 
11 P. Selwyn & M. Forstein, “Overcoming the False Dichotomy of Curative vs. Palliative Care for Late-Stage HIV/AIDS,” Journal 
of the American Medical Association, vol. 290 (2003) pp. 806-814. 
12 M. C. Dalakas, “Peripheral Neuropathy and Antiretroviral Drugs”, Journal of the Peripheral Nervous System, vol. 6, no. 1 
(2001) pp. 14-20; Several studies have found that between 29 and 74 percent of people who receive antiretroviral treatment 
experience pain symptoms: K. Green, Evaluating the Delivery of HIV Palliative Care Services in Out-Patient Clinics in Viet Nam, 
Upgrading Document, London School of Hygiene and Tropical Medicine (2008). 
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concentrate, sleep, or interact with others.13 A WHO study found that people who live with 
chronic pain are four times more likely to suffer from depression or anxiety.14 The physical 
and psychological effects of chronic pain can directly influence the course of disease and 
also reduce patients’ adherence to treatment.15  
 
Pain also has social consequences for patients and their caregivers, including inability to 
work, care for children or other family members, and participate in social activities.16 At the 
end of life, pain can interfere with a patient’s ability to bid farewell to loved ones and make 
final arrangements. 
 
Impact of Palliative Care and Pain Management 
Most suffering caused by pain is avoidable as medicines to treat pain are effective, safe, 
inexpensive, and generally easy to administer.17 WHO’s Pain Relief Ladder recommends the use 
of increasingly potent painkillers as pain becomes more severe, from basic pain medicines 
(such as acetaminophen, aspirin, or ibuprofen) to strong pain medicines such as morphine.18 
 
Like morphine, all strong painkillers are opioids: extracts of the poppy plant or similar synthetic 
drugs. WHO’s Model List of Essential Medicines includes morphine in oral tablet, oral solution, 
and injectable formulations.19 For chronic pain management, WHO recommends oral morphine 
given at regular intervals around the clock.20 Patients can easily take oral morphine in their own 
homes and prescribing it avoids the pain of regular injections, which is especially important for 
children and patients whose muscle tissue is emaciated by cancer or HIV/AIDS. Similarly, with 
relatively inexpensive interventions, palliative care providers can treat a variety of other 
                                                          
13 F. Brennan, D.B. Carr and M. Cousins, “Pain Management: A Fundamental Human Right,” Anesthesia & Analgesia, vol. 105 
(2007) pp. 205-221. 
14 O. Gureje et al., “Persistent Pain and Well-Being: A World Health Organization Study in Primary Care”, Journal of the 
American Medical Association, vol. 280 (1998) pp. 147-51. See also: B. Rosenfeld et al., “Pain in Ambulatory AIDS Patients. II: 
Impact of Pain on Psychological Functioning and Quality of Life," Pain, vol. 68, no. 2-3 (1996) pp. 323–28. 
15 B. Rosenfeld et al., “Pain in Ambulatory AIDS Patients. II: Impact of Pain on Psychological Functioning and Quality of Life,” 
Pain, pp. 323 – 28.  
16 R. L. Daut et al., “Development of the Wisconsin Brief Pain Questionnaire to Assess Pain in Cancer and Other Diseases,” 
Pain, vol. 17, no. 2 (1983) pp. 197 – 210. 
17 World Health Organization, “Achieving Balance in National Opioid Control Policy,” 2000, 
http://apps.who.int/medicinedocs/en/d/Jwhozip39e/ (accessed August 6, 2010).  
18 World Health Organization, “WHO’s Pain Ladder,” 2010, http://www.who.int/cancer/palliative/painladder/en/ (accessed 
August 6, 2010). This has been developed for cancer but is also referred to for other conditions.  
19 World Health Organization, “Model List of Essential Medicines - 16th List,” March 2009, 
http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf (accessed 6 August 2010). 
20 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability 14 (2nd ed. 1996).  
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symptoms that are common among people with life-threatening illnesses, including 
breathlessness, nausea, anxiety, and depression. 
 
Numerous studies have shown that patients who receive palliative care enjoy greater quality 
of life, have fewer distressing physical symptoms, and a lower incidence of depression or 
anxiety. A recent study published in the New England Journal of Medicine found that, in 
addition to improving quality of life, when palliative care was started shortly after diagnosis 
in patients with metastatic lung cancer, they actually lived an average of three months 
longer than patients that did not have access to palliative care.21 
 
The Palliative Care and Pain Treatment Gap 
WHO and the INCB have repeatedly drawn attention to the enormous unmet need for pain 
treatment and called for countries to meet this need through low-cost palliative care services. 
WHO estimates that tens of millions of people each year suffer untreated moderate to severe 
pain, including 5.5 million terminal cancer patients and 1 million patients in the last phases 
of HIV/AIDS. The president of the INCB has stated that access to morphine and other strong 
pain medicines is “virtually non-existent in over 150 countries.”22  
 
In 2006 the International Observatory on End of Life Care published a study that found that 
no palliative care activity could be identified in 78 of 234 countries reviewed; in 41 countries 
it found some preparation for palliative care delivery but no actual services; and in 80 
countries it found “localized provision” of palliative care by a small number of isolated 
services. In only 35 countries did the study find that palliative care was “approaching 
integration” into health services.23 
 
 
 
                                                          
21 Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., Alona Muzikansky, M.A., Emily R. Gallagher, R.N., Sonal Admane, M.B., B.S., 
M.P.H., Vicki A. Jackson, M.D., M.P.H., Constance M. Dahlin, A.P.N., Craig D. Blinderman, M.D., Juliet Jacobsen, M.D., William F. 
Pirl, M.D., M.P.H., J. Andrew Billings, M.D., and Thomas J. Lynch, M.D., Early Palliative Care for Patients with Metastatic Non–
Small-Cell Lung Cancer N Engl J Med 2010; 363:733-742, August 19, 2010 
22“Briefing Note: Access to Controlled Medicines Program,” World Health Organisation Briefing Note, February 2009, 
http://www.who.int/medicines/areas/quality_safety/ACMP_BrNoteGenrl_EN_Feb09.pdf (accessed August 6, 2010); Sevil 
Atasoy, Statement by Professor Sevil Atasoy President of the International Narcotics Control Board (2009) 
http://www.incb.org/documents/President_statements_09/2009_ECOSOC_Substantive_Session_published.pdf p. 2; World 
Health Organization, “Model List of Essential Medicines - 16th List,” March 2009, 
http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf (accessed August 6, 2010).  
23 Michael Wright and others, “Mapping levels of palliative care development: a global view,” International Observatory on End of Life 
Care, Lancaster University, November 2006, www.eolc-observatory.net/global/pdr/world_map.pdf (accessed February 10, 2011). 
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Barriers to Palliative Care and Pain Treatment 
There is no lack of information about the reasons why so many people who suffer from life-
limiting illnesses do not have access to adequate pain treatment and palliative care. In 
dozens of publications spanning several decades, WHO, INCB, health care providers, 
academics and others have chronicled the barriers in great detail.24 A common theme of 
many of these publications is the failure of many governments around the world to take 
reasonable steps to improve access to pain treatment and palliative care services.  
 
Barriers can be divided into three areas: lack of health policies in support of palliative care 
development; lack of relevant training for healthcare workers; and poor availability of 
essential palliative care drugs. Within this latter category, there are a number of different 
common barriers, including the failure of states to put in place functioning drug supply 
systems, existence of unnecessarily restrictive drug control regulations and practices, fear 
among healthcare workers of legal sanctions for legitimate prescribing of opioid medications, 
and the unnecessarily high cost of pain medications. A more detailed discussion of these 
barriers can be found in Human Rights Watch’s March 2009 report, “Please do not make us 
suffer anymore…”: Access to Pain Treatment as a Human Right. 
                                                          
24 Human Rights Watch, “Please, do not make us suffer any more…”: Access to Pain Treatment as Human Right, March 2009, 
http://www.hrw.org/sites/default/files/reports/health0309web_1.pdf. 
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II. Survey Findings: Global Overview of Barriers to Pain Treatment 
 
Our survey mapped barriers to palliative care related to health policy, education of 
healthcare workers, and drug availability in 40 countries. We asked healthcare workers 
questions about a number of common barriers in each of these areas to understand how 
widespread they are. The questions are based on research that Human Rights Watch 
previously conducted for its March 2009 report, “Please, do not make us suffer anymore…”: 
Access to Pain Treatment as a Human Right.25 
 
The results of this survey confirm the general findings in that report but provide a more 
detailed picture of the specific barriers that exist in individual countries, as well as the 
prevalence of these barriers internationally. They provide a roadmap for individual countries 
and the international community for steps they need to take to improve palliative care 
availability. Our comparisons of consumption of opioid medications with mortality figures 
for cancer and HIV/AIDS demonstrate just how poor the availability of pain treatment is in 
many countries around the world. 
 
We found enormous unmet need for pain treatment. Fourteen countries—Antigua and Barbuda, 
Bolivia, Cameroon, Comoros, Djibouti, Gambia, Guinea, Guinea-Bissau, Kiribati, Honduras, 
Swaziland, Solomon Islands, Tanzania and Tuvalu—reported no consumption of opioid pain 
medicines between 2006 and 2008, meaning that there are no medicines to treat moderate to 
severe pain available through legitimate medical channels in those countries.  
 
In a further eight countries that do not report opioid consumption to the International 
Narcotics Control Board—Afghanistan, Belize, Equatorial Guinea, Fiji, Liberia, Niue, Somalia, 
and Timor-Leste—the situation is likely similar, as countries that participate in the 
international drug control regime undertake not to export opioids to these countries. 
Thirteen other countries—Burkina Faso, Burundi, Cambodia, Central African Republic, Chad, 
Cote d’Ivoire, Ethiopia, Haiti, Malawi, Mali, Niger, Nigeria, and Rwanda—do not consume 
enough opioids to treat even one percent of their terminal cancer and HIV/AIDS patients.  
 
Of course, this means that in all of these countries, each year tens of thousands of patients 
suffer unnecessary pain. For example in Nigeria, more than 173,000 people with terminal cancer 
and HIV/AIDS patients need treatment for moderate to severe pain each year, but all the 
                                                          
25 Human Rights Watch, “Please, do not make us suffer any more…”: Access to Pain Treatment as Human Right, March 2009, 
http://www.hrw.org/sites/default/files/reports/health0309web_1.pdf. See Appendix 2 for survey questions.  
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opioids consumed in Nigeria could treat just 274 such patients. In Ethiopia, more than 85,000 
such patients need treatment, but there are drugs for less than 500. Less populous Cambodia 
still has more than 14,000 terminal cancer and HIV/AIDS patients suffering pain each year but 
drugs to treat just 91 of them. In addition to Nigeria, China, India, Indonesia, and Russia all 
have poor availability of opioids for pain relief and more than 100,000 patients who die from 
cancer or HIV/AIDS each year without access to adequate pain treatment. 
 
The combined suffering due to lack of opioid pain medicines worldwide is staggering. Our 
calculations confirm that more than 3.5 million terminal cancer and HIV/AIDS patients die 
each year without access to adequate pain treatment. This includes at least 1.7 million 
terminal cancer and HIV/AIDS patients in Asia, 1.2 million in sub-Saharan Africa, 480,000 in 
Europe, 180,000 in the Middle East and North Africa, and 100,000 in the Americas. It must 
be emphasized that these are very conservative estimates, which assume that all opioids 
are used to treat this patient group. This is why it is lower than WHO’s estimate that each 
year 5.5 million terminal cancer patients and 1 million patients in the last phases of 
HIV/AIDS suffer without pain treatment.26  
 
Our calculations focus on patients with terminal cancer and HIV/AIDS because their need is 
great and because mortality data is available for these causes for most countries but not for 
many other diseases that cause immense pain. In reality, the limited opioids that are 
available are used to treat patients suffering pain from other causes, so the real number of 
terminal cancer and HIV/AIDS patients with untreated pain must be higher, and many other 
patients with non-terminal cancer, HIV/AIDS, and with other diseases are also suffering 
untreated pain. Consequently, the unmet need of terminal cancer and HIV/AIDS patients 
must be considered merely an indicator of even greater unmet need for pain treatment.  
 
Availability of Policies that Promote Palliative Care and Pain Treatment 
WHO has stressed the importance of comprehensive strategies to improve access to 
palliative care.27 Without such policies, it is difficult to ensure that all relevant government 
and nongovernment agencies act in a coordinated fashion to address all barriers that 
impede the development of palliative care simultaneously. Under the right to health, 
                                                          
26 “Briefing Note: Access to Controlled Medicines Program,” World Health Organisation Briefing Note, February 2009, 
http://www.who.int/medicines/areas/quality_safety/ACMP_BrNoteGenrl_EN_Feb09.pdf (accessed August 6, 2010). 
27 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability, (2nd ed. 1996). The need for a comprehensive 
palliative care policies is also stressed by academic experts: Stjernsward, J. & D. Clark, Palliative Medicine: A Global Perspective, in 
Derek Doyle et al., eds., Oxford Textbook of Palliative Medicine (Oxford: Oxford University Press, 3rd ed. 2003) pp. 1199-1222; DFID 
Health Resource Center, Review of Global Policy Architecture and Country Level Practice on HIV/AIDS and Palliative Care (2007).  
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countries are obliged to develop health policies that address the needs of the entire 
population, including people facing life-threatening illnesses.28 
 
In our survey, we sought information about the availability of national palliative care policies; 
whether palliative care was addressed in national cancer and HIV control policies or plans; and 
whether oral and injectable morphine were included on national essential medicines lists. 
 
National Palliative Care Policies: Of the 40 countries surveyed, 29 did not have a 
national palliative care policy. Those that did are Argentina, Brazil, Indonesia, France, 
the Philippines, Poland, South Korea, Turkey, Uganda, the UK, and Vietnam. 
Although survey respondents were not directly asked about implementation, in two 
of these countries, Argentina and Brazil, the respondents told Human Rights Watch 
that the governments were not actually implementing the palliative care policies.29 In 
Indonesia, survey respondents said that policies were only partially implemented.30 
 
National Cancer Control Policies and Plans: National cancer control policies and 
plans of 24 of the 40 countries surveyed make reference to pain management or 
palliative care. Eight countries do not have a national cancer control policy or plan at 
all. In some countries, like India, the reference to palliative care is essentially 
rhetorical as it is not backed up by an action plan, targets, or budget allocation.31 It is 
not clear in how many of the other countries surveyed that is the case. 
 
National HIV/AIDS Control Policies and Plans: In 23 countries surveyed, national 
AIDS control policies did not make reference to palliative care, including three high-
burden countries—Cameroon, Ethiopia, and Kenya.32 AIDS control policies in 11 
countries surveyed made reference to palliative care, including a number of high 
burden countries like South Africa, Tanzania, Nigeria, and Uganda. Four of the 
countries surveyed do not have a national AIDS control policy at all. 
 
                                                          
28 UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the 
International Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable 
Standard of Health, E/C.12/2000/4 (2000), http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915. 
29 Human Rights Watch email correspondence with Dr Roberto Wenk, Argentina, October 18, 2010; Human Rights Watch email 
correspondence with Dr Roberto Bettega, Brazil, December 10, 2010.  
30 Human Rights Watch interviews with Indonesian doctors who requested anonymity, January 19, 2010, and November 5, 2010.  
31 Human Rights Watch, Unbearable Pain: India’s Obligation to Ensure Palliative Care, October 2009, 
http://www.hrw.org/en/reports/2009/10/28/unbearable-pain-0.  
32 “High-burden” is defined as adult HIV prevalence greater than 5%; data from UNAIDS, Report on the Global AIDS Epidemic, 
2010, http://www.unaids.org/globalreport/ (accessed March 11, 2011).  
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The fact that palliative care was mentioned in more than twice as many cancer 
policies may reflect the fact that palliative care has long been associated with 
cancer control. For example, WHO has made extensive recommendations on 
developing palliative care as part of cancer control programs but has said little 
about its importance for patients with other diseases.33 Palliative care and pain 
treatment have often been neglected in national and international responses to 
HIV/AIDS, despite significant prevalence of pain and other symptoms in people 
living with HIV/AIDS.34 
 
National Essential Medicines Lists: WHO considers injectable and oral morphine 
essential medicines for the treatment of pain that should be available to all people 
who need them.35 Of the countries surveyed, only South Korea did not have 
injectable morphine on its essential medicines list; six had not included oral 
morphine: South Korea, Tanzania, Egypt, Iran, Ukraine and Georgia. Three countries–
Germany, the United Kingdom (UK), and the United States (US)—do not have an 
essential medicines list.  
 
Training for Healthcare Workers 
One of the largest obstacles to the provision of good palliative care and pain treatment 
services in many countries is the lack of training for healthcare workers. Many do not have 
an adequate understanding of palliative care, do not know how to provide it and subscribe 
to various myths about morphine and other opioid analgesics. Key informants from 16 
                                                          
33 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability, (2nd ed. 1996); World Health Organization, 
“National Cancer Control Programs: Policies and Managerial Guidelines,” 2002, 
http://www.who.int/cancer/media/en/408.pdf (accessed August 6, 2010), pp. 86. 
34 K. Green, Evaluating the Delivery of HIV Palliative Care Services in Out-Patient Clinics in Viet Nam, Upgrading 
Document, London School of Hygiene and Tropical Medicine (2008); Kathleen M. Foley et al., “Pain Control for People 
with Cancer and AIDS,” in Dean T Jamison et al., Disease Control Priorities in Developing Countries (Washington: World 
Bank Publications, 2nd ed. 2003), pp. 981-994; Francois Larue et al., “Underestimation and Under-Treatment of Pain in 
HIV Disease: A Multicentre Study,” British Medical Journal, vol. 314 (1997) 
http://www.bmj.com/cgi/content/full/314/7073/23 (accessed August 6, 2010) p. 23; J. Schofferman & R. Brody, Pain in 
Far Advanced AIDS, in K. M. Foley et al., eds., Advances in Pain Research and Therapy (1990) pp. 379-386; E. J. Singer et 
al., “Painful Symptoms Reported by Ambulatory HIV-Infected Men in a Longitudinal Study," Pain, vol. 54 (1993) pp. 15-19; 
P. Selwyn & M. Forstein, “Overcoming the False Dichotomy of Curative vs. Palliative Care for Late-Stage HIV/AIDS,” 
Journal of the American Medical Association, vol. 290 (2003) pp. 806-814; Richard Harding et al., “Does Palliative Care 
Improve Outcomes for patients with HIV/AIDS: A systematic review of the evidence,” Sexually Transmitted Infections , 
vol. 81 (2005), pp. 5-14; Justin Amery et al., “The Beginning of Children’s Palliative Care in Africa: Evaluation of a 
Children’s Palliative Care Service in Africa,” Journal of Palliative Medicine, vol. 12 (2009), pp. 1015-1021. 
35 World Health Organization, “Model List of Essential Medicines - 16th List,” March 2009, 
http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf (accessed August 6, 2010), 
includes the following opioid analgesics: Codeine Tablet: 30 mg (phosphate); Morphine Injection: 10 mg (morphine 
hydrochloride or morphine sulfate) in 1‐ml ampoule; Oral liquid: 10 mg (morphine hydrochloride or morphine sulfate)/5 ml., 
Tablet: 10 mg (morphine sulfate); Tablet (prolonged release): 10 mg; 30 mg; 60 mg (morphine sulfate). 
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countries surveyed told us when asked whether healthcare workers feared potential legal 
repercussions when using opioid medications that the bigger problem was that healthcare 
workers in their countries were reluctant to use opioid medications because of exaggerated 
fears that they would cause dependence syndrome or respiratory distress in patients.36 
 
To overcome these obstacles, WHO has recommended that countries provide training on 
palliative care to healthcare workers.37 Under the right to health, countries are obliged to 
ensure that healthcare workers at least receive training in the basics of palliative care.38 
Given that almost all doctors will encounter patients in need of palliative care and pain 
treatment, instruction in these disciplines should be a standard part of undergraduate 
medical curriculum and postgraduate training in medical disciplines that routinely deal with 
patients who require palliative care. 
 
In our survey, we sought information on the availability of instruction on palliative care in 
undergraduate and postgraduate medical studies as well as continuing medical education. 
We also asked key informants whether palliative care instruction in undergraduate studies 
was mandatory. 
 
Undergraduate Medical Studies: Instruction in pain management (whether or not as 
part of instruction in palliative care) was available in all undergraduate programs in just 
five countries surveyed (France, Kenya, Poland, Uganda, and the United Kingdom). It 
was compulsory for undergraduate medical students in four of them: France, Poland, 
Uganda, and the United Kingdom. In Germany, compulsory instruction in palliative care 
in undergraduate medical studies will gradually be introduced starting in 2014.39 In 33 
of 40 countries instruction in pain management is available in some undergraduate 
medical programs.  
 
Postgraduate Medical Studies: In the majority of surveyed countries—31 of 40—
survey respondents reported that there are opportunities for postgraduate training in 
pain management (either as part of palliative care instruction or separately). In 
Ethiopia, Tanzania, Cameroon, Guatemala, Iran, Jordan, and China there is no 
postgraduate training in palliative care available at all. Many respondents, 
                                                          
36 Such fears were mentioned by healthcare workers from Bangladesh, Brazil, Cambodia, Cameroon, China, Colombia, the 
Dominican Republic, Ethiopia, Guatemala, Nepal, Philippines, South Africa, South Korea, Tanzania, Thailand, and Vietnam. 
37 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability (2nd ed. 1996). 
38 See Chapter IX for more detail on governments’ obligation to ensure that healthcare workers receive education in palliative care. 
39 Human Rights Watch interview with Professor Lucas Radbruch, Germany, February 4, 2010.  
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particularly in Africa and Asia, stated that healthcare workers who wanted to 
specialize in palliative care completed postgraduate training by correspondence or 
in foreign countries.  
 
Drug Availability 
Because of their potential for abuse, morphine and all other strong pain medicines are 
regulated under the Single Convention on Narcotic Drugs and national drug-control laws 
and regulations.40 This means that their manufacture, import and export, distribution, 
prescription, and dispensation can only occur with government authorization, overseen 
by a body created by the Single Convention, the International Narcotics Control Board.  
 
The fact that morphine and other strong analgesics are controlled medications has given 
rise to a host of problems related to their availability, as countries have struggled to put 
in place functioning supply and distribution systems; their accessibility, as many 
countries have enacted drug control laws that make it difficult for doctors to prescribe the 
medications and for patients to receive them; and their cost, as control measures and 
other factors have unnecessarily driven up the price of these medications, which can be 
produced at very low cost. 
 
WHO has urged countries to put in place functioning supply and distribution systems and to 
ensure that drug control measures do not unnecessarily impede their availability and 
accessibility.41 Under the UN drug conventions, countries are obliged to ensure the 
“adequate provision” of controlled medications while preventing their misuse or diversion.42 
Under international human rights law, countries are obliged to ensure the availability and 
accessibility of essential medications like morphine.43 
 
In our survey, we sought information to assess the quality of countries’ supply and distribution 
systems for opioid analgesics, their drug regulations, and the cost of opioid analgesics. 
 
 
                                                          
40 Single Convention on Narcotic Drugs, United Nations, Single Convention on Narcotic Drugs (1961) 
http://www.incb.org/pdf/e/conv/convention_1961_en.pdf (accessed August 6, 2010). 
41 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability (2nd ed. 1996). 
42 Single Convention on Narcotic Drugs, United Nations, Single Convention on Narcotic Drugs (1961) 
http://www.incb.org/pdf/e/conv/convention_1961_en.pdf (accessed August 6, 2010), preamble. 
43 UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the International 
Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable Standard of 
Health, E/C.12/2000/4 (2000), http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915 para. 43. 
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Supply and Distribution System for Opioid Analgesics 
As the import, production, and distribution of controlled medicines are under exclusive 
government control, they will simply not be available without government action to put in 
place effective supply systems. Governments need to provide annual estimates to the INCB 
for the amounts of morphine and other opioid medications needed. They must also approve 
production or import of such medications; provide licenses to health care providers and 
pharmacies before these can stock and dispense them; and authorize movements between 
producers, pharmacies, and health facilities. 
 
In our survey, we sought to establish how widely available morphine is in different types of 
healthcare facilities in countries as a way of measuring the effectiveness of the supply and 
distribution systems governments have put in place. In particular, we asked about the 
availability of injectable morphine in hospitals and oral morphine in tertiary hospitals, other 
hospitals, pharmacies, health centers, hospices, and AIDS clinics. We also asked whether, in 
the experience of the key informants, morphine was harder to access outside major cities and 
whether health care providers were involved in developing their government’s estimates of its 
need for opioid medications. 
 
Injectable Morphine: Key informants reported that injectable morphine is 
available in all hospitals in just 10 of the 40 countries surveyed: France, Georgia, 
Iran, Japan, Poland, Russia, Thailand, Turkey, the UK, and the US. In a further 12 
countries, it was reported to be available in most hospitals. Key informants said 
that injectable morphine was available only in “some” hospitals in the remaining 
18 countries. 
 
Oral Morphine: Two countries surveyed, Ukraine and Iran, do not have oral 
morphine at all. In Ukraine, despite recommendations by WHO to the contrary, 
injectable morphine is used to treat chronic pain, while in Iran a weaker oral 
opioid, Tramadol, is used. Table 1 contains an overview of the data on availability 
of oral morphine in the various healthcare settings. 
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Table 1: Availability of Oral Morphine in Different Healthcare Settings in Countries Surveyed 
Health facility None Few Some Most All Don’t know N/A 
Tertiary hospitals 3 - 19 6 12 - - 
Other hospitals 6 3 14 9 4 4 - 
Pharmacies 6 5 24 3 2 - - 
Health centers 22 5 10 3 - - - 
Hospices 5 1 8 7 13 - 6 
AIDS clinics 17 1 7 3 3 5 4 
 
The table demonstrates that oral morphine is generally most widely available in tertiary 
hospitals and hospices; somewhat less available in pharmacies and smaller hospitals; and 
least likely to be available in health centers or AIDS clinics. In other words, patients with 
pain often need to be referred to larger health facilities, making pain treatment less 
accessible and more costly for them.  
 
Poor availability of oral morphine in smaller healthcare facilities also compounds access 
problems for people who live far from major cities, where larger health facilities are likely 
to be located. In many developing countries, distance and the cost of travel make it very 
difficult for people living in rural areas to reach any health facility, but their closest facility 
is likely to be a small clinic or health centre or perhaps a pharmacy or small hospital. As 
oral morphine and other opioids are less likely to be available in these settings than in 
larger hospitals, rural patients’ barriers to accessing pain treatments are compounded.44  
 
A key component of a functioning supply and distribution system is a robust process to 
estimate the need for opioid medications. WHO has recommended that the government 
involve healthcare workers in developing such estimates.45 In 23 of the countries surveyed, 
healthcare workers, who were mostly leading palliative care or pain management specialists, 
were not aware of any such consultations.46 In several other countries, survey respondents 
                                                          
44 For more discussion of this problem in one particular country, Kenya, see Human Rights Watch, Needless Pain: Government 
Failure to Provide Palliative Care for Children in Kenya, September 2010, 
http://www.hrw.org/en/reports/2010/09/09/needless-pain-0.  
45 WHO, Cancer Pain Relief: with a guide to opioid availability, 2nd ed. (Geneva: World Health Organization, 1996), 
http://whqlibdoc.who.int/publications/9241544821.pdf (accessed February 20, 2011), p. 49.  
46 Argentina, Bangladesh, Cambodia, Cameroon, China, Ecuador, Egypt, El Salvador, Ethiopia, Germany, Guatemala, 
India, Indonesia, Iran, Kenya, Nepal, Pakistan, Philippines, South Africa, South Korea, Thailand, the United Kingdom and 
the United States. In Germany, South Korea, the United Kingdom and the United States, survey respondents commented 
that as there is good availability of opioids and complete consumption data is available to the government, such 
consultations are probably unnecessary.  
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reported occasional consultations that were thought to be inadequate or have no real affect 
on the estimates process.47  
 
Unsurprisingly, industrialized countries like Germany, France, the United Kingdom, and the 
United States had widespread availability of oral morphine across these settings. Besides Iran 
and Ukraine, which have no oral morphine, other countries that stood out as having particularly 
poor accessibility across the various health settings were scattered throughout the regions and 
included Bangladesh, Cameroon, Ethiopia, Georgia, Guatemala, Morocco, and Pakistan.  
 
Drug Regulations 
The Single Convention on Narcotic Drugs lays out three minimum criteria that countries 
must observe when developing national regulations governing the handling of opioids. 
First, individuals must be authorized to dispense opioids by their professional license to 
practice or be specially licensed to do so. Secondly, movement of opioids may only occur 
between institutions or individuals so authorized under national law. Finally, a medical 
prescription is required before opioids may be dispensed to a patient. Governments may, 
under the convention, impose additional requirements if deemed necessary.48 But WHO 
has observed that the right to impose additional requirements “must be continually 
balanced against the responsibility to ensure opioid availability for medical purposes.”49 
 
Many countries have adopted regulations that go well beyond the requirements of the Single 
Convention, often creating complex procedures for procurement, stocking, and dispensing of 
controlled medications that impede their accessibility for patients with a legitimate medical 
need. Under the UN drug conventions and international human rights law, countries must 
balance their efforts to prevent the misuse of controlled substances against the obligation to 
make them available to patients who need them.50 Drug control regulations that have a 
                                                          
47 France, Jordan, Morocco, Nigeria, Ukraine, and Vietnam.  
48 United Nations, Single Convention on Narcotic Drugs (1961). http://www.incb.org/incb/convention_1961.html (accessed 
August 6, 2010).  
49 WHO, Cancer Pain Relief: with a guide to opioid availability, 2nd ed. (Geneva: World Health Organization, 1996), 
http://whqlibdoc.who.int/publications/9241544821.pdf (accessed February 20, 2011), p. 56. 
50 Single Convention on Narcotic Drugs, United Nations, Single Convention on Narcotic Drugs (1961) 
http://www.incb.org/pdf/e/conv/convention_1961_en.pdf (accessed August 6, 2010), preamble; UN Committee on Economic, 
Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the International Covenant on Economic, 
Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable Standard of Health, E/C.12/2000/4 
(2000), http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915 
005090be?Opendocument (accessed January 17, 2010), para. 43; WHO, Cancer Pain Relief: with a guide to opioid 
availability, 2nd ed. (Geneva: World Health Organization, 1996), 
http://whqlibdoc.who.int/publications/9241544821.pdf (accessed February 20, 2011), p. 56; Human Rights Watch, “Please, 
do not make us suffer any more…”: Access to Pain Treatment as Human Right, March 2009, 
http://www.hrw.org/sites/default/files/reports/health0309web_1.pdf.  
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disproportionately negative effect on availability and accessibility of controlled medications 
will violate both drug conventions and human rights treaties. 
 
In our survey, we collected information about three types of regulations that are commonly 
reported to limit the accessibility of controlled medicines: special licensing requirements for 
healthcare workers; use of special prescription forms and other special prescription 
requirements; and limits on the amount of morphine that can be prescribed using one 
prescription or the length of time that a prescription can cover. We also asked key 
informants whether, in their experience, doctors were reluctant to prescribe opioid 
medications because of worries about potential legal scrutiny. 
 
Special Licensing Requirements: The Single Convention on Narcotic Drugs requires 
that people who handle opioid medications be licensed to do so. The convention 
does not require a special license and in many countries healthcare workers are 
licensed to handle such medications by virtue of their professional license. Yet many 
countries require a special license and some allow only certain types of doctors to 
prescribe opioid medications. WHO has recommended that “physicians, nurses and 
pharmacists should be legally empowered to prescribe, dispense and administer 
opioids to patients in accordance with local needs.”51 As patients who suffer pain 
have a right to access essential medicines including morphine, the right to the 
highest attainable standard of health requires that limits on which healthcare 
workers can prescribe opioids be no more restrictive than is reasonably necessary to 
prevent their diversion to misuse.52  
 
Fourteen of the forty countries surveyed require doctors to obtain a special license or 
registration in order to prescribe controlled medications. Survey respondents in 
some countries, such as the United States, said that the process for obtaining this 
special license is simple and almost all doctors have one.53 Others said that 
obtaining the necessary license requires considerable paperwork or even invasive 
screening of the doctor. For example, the Philippines requires doctors applying for a 
license to submit urine for drug tests.54 In Ukraine, doctors must obtain certificates 
from the police department and drug treatment clinic that they do not have a 
                                                          
51 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability 10 (2nd ed. 1996).  
52 See Chapter VII for more detail on governments’ obligation to make pain medicines available under the right to the highest 
available standard of health.  
53 Human Rights Watch interview with Don Schumacher, president and CEO, National Hospice and Palliative Care Association, 
United States of America, February 8, 2010.  
54 Human Rights Watch interview with Dr Francis Javier, Director, Pain Management Centre, Philippines, August 26, 2009.  
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criminal record or are not registered as drug users. Survey respondents from 
Morocco and the Philippines stated that, as a result of complex licensing procedures, 
very few doctors have a license to prescribe opioids.55  
 
Egypt, Ukraine, and Georgia limit the right to prescribe opioids to doctors practicing in 
certain specialties, commonly oncology, pain management, or anesthesiology.56 In 
Russia, physicians who do not work in the government health care system cannot 
prescribe opioids.57  
 
Only 2 of 40 countries, Uganda and the United Kingdom, allow nurses to prescribe 
controlled medicines in certain circumstances. In a third country, the United States, 
most but not all states allow nurses to prescribe. In South Africa, efforts to 
introduce nurse-prescribing are underway.58 Nurse-prescribing is essential in 
resource-limited settings where doctor-patient ratios are very low and many people 
never see a doctor in their lifetime.59 The INCB has commended Uganda for 
introducing nurse-prescribing.60  
 
Special Prescription Requirements: The Single Convention does not require 
prescriptions for controlled medicines to be written on special prescription forms 
but does explicitly permit this practice. WHO has observed that special multiple-
copy prescription requirements “typically reduce prescribing of covered drugs by 
50 percent or more.”61 While the use of special prescription forms and procedures 
is not by definition inconsistent with the right to health, they must be easily 
accessible for healthcare workers and not add cost to the medicines. 
 
                                                          
55 Ibid.; Human Rights Watch interviews with Professor Mhamed Harif and Dr Maati Nejmi, Morocco, January 21, 2010. 
56 Human Rights Watch email correspondence with an Egyptian pain management specialist who requested anonymity, Egypt, 
October 7, 2010; Nathan I. Cherney et al., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer 
Pain in Europe: A Report from the ESMO/EAPC Opioid Policy Initiative,” Annals of Oncology, vol. 21, no. 3 (2010).  
57 Human Rights Watch email correspondence with a Russian doctor who requested anonymity, December 12, 2010.  
58 Human Rights Watch interview with Don Schumacher, February 8, 2010; Human Rights Watch interview with Dr. Bill 
Noble, Macmillan Senior Lecturer in Palliative Medicine, Sheffield University, United Kingdom, December 14, 2009; 
Human Rights Watch interview with Dr Liz Gwyther, CEO, Hospice Palliative Care Association of South Africa, South Africa, 
October 6, 2010; Human Rights Watch interview with Dr Henry Ddungu, advocacy manager, African Palliative Care 
Association, Uganda, August 10, 2009.  
59 J. Jagwe and A. Merriman, “Uganda: Delivering Analgesia in Rural Africa: Opioid Availability and Nurse-prescribing,” Journal 
of Pain and Symptom Management, vol. 33 no. 5 (2007), p. 547. 
60 International Narcotics Control Board, “Report of the International Narcotics Control Board for 2004,” E.05.XI.3, 2005, 
http://www.incb.org/pdf/e/ar/2004/incb_report_2004_full.pdf (accessed October 28, 2010), para. 196.  
61 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability 10 (2nd ed. 1996). 
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Our survey found that 30 of the 40 countries surveyed require special prescription 
forms. In two countries, Germany and Morocco, survey respondents mentioned that 
doctors have to apply to receive the forms; in the Philippines they have to pay for 
them.62 Survey respondents in three countries, El Salvador, Turkey, and Ukraine, 
mentioned problems accessing enough special prescription forms.63  
 
In three countries, Russia, Ukraine and—for longer prescriptions—Turkey, 
prescriptions for morphine must be approved by more than one doctor. In Ukraine, 
such prescriptions must be made by a group of three doctors, one of whom must be 
an oncologist, and approved by the chief doctor of the hospital.64 
 
Prescription Limitations: WHO has recommended that “decisions concerning the 
type of drug to be used, the amount of the prescription and the duration of 
therapy are best made by medical professionals on the basis of the individual 
needs of each patient, not by regulation.”65 Yet, many countries have regulations 
that unnecessarily constrict these medical decisions, in violation of patients’ 
right to the highest attainable standard of health.66  
 
Our survey found that 25 of the 40 countries surveyed impose limits of these 
kinds. Some countries, including Ukraine and Turkey, limit the daily dose of 
morphine that can be prescribed and others, including Germany, Egypt, and 
Russia, limit the amount that can be prescribed in one prescription, and others, 
including the Philippines, set a maximum monthly dose. Other countries limit the 
number of days that a morphine prescription can cover. In our survey, the 
shortest daily limits were seven days in Cambodia, Egypt, Morocco, and Georgia, 
and ten days in Argentina, Russia, and Ukraine. Jordan imposes a limit of ten 
                                                          
62 Human Rights Watch interview with Dr Maati Nejmi, January 21, 2010; Human Rights Watch interviews with Professor Lucas 
Radbruch, Palliative Medicine, Aachen University, Germany, February 4, 2010, Professor Rolf-Detlef Treede, president of the 
German Pain Society, Germany, October 12, 2009, and Dr Henry Lu, immediate past president of the Pain Society of the 
Philippines, Philippines, September 2, 2009.  
63 Human Rights Watch interview with Professor Serdar Erdine, chairman, Department of Pain Management, Istanbul 
University, president of the Turkish Society of Pain Management, Turkey, November 19, 2009; Human Rights Watch 
Interviews with Dr Larin Lovo and Dr Carlos Eduardo Rivas, El Salvador, 2010; Human Rights Watch interview with Viktoria 
Tymoshevska, International Palliative Care Initiative, Ukraine, September 24, 2010; Human Rights Watch interview 
Nathan I. Cherney et al., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in 
Europe: A Report from the ESMO/EAPC Opioid Policy Initiative,” Annals of Oncology, vol. 21, no. 3 (2010), p. 620.  
64 The Ministry of Health of Ukraine: Order No. 356; Human Rights Watch interview with Victoria Tymosnevska, Ukraine, 
September 24, 2010. 
65 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability 10-11 (2nd ed. 1996). 
66 See Chapter VIII for more detail on governments’ obligation to make pain medicines available under the right to the highest 
available standard of health.  
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days for cancer patients and just three days for other patients. In China, the limit 
varies according to the morphine formulation, fifteen days for immediate release 
morphine tablets, seven days for slow release tablets, and just three days for 
injectable morphine.67  
 
Fourteen of the countries surveyed do not impose a time limit on the number of days 
one prescription can cover: the United States, Germany, Turkey, the United Kingdom, 
Pakistan, Nigeria, Uganda, Tanzania, Nepal, India, Ethiopia, Indonesia, Kenya, and 
South Korea. Another 15 of the countries maintained a limit of 28 to 30 days.  
 
Fears of Legal Sanction: Regulations that contain ambiguous standards regarding 
medical prescription and handling of opioids, or punish mishandling harshly, can 
chill legitimate prescribing. The INCB has said the “vast majority of health 
professionals exercise their activity within the law and should be able to do so 
without unnecessary fear of sanctions for unintended violations.”68 Criminalizing 
unintentional mistakes in opioid prescription is not consistent with the right to 
health.69 Countries must ensure that regulations are unambiguous and that 
complete information about them is readily available for health care providers, so 
that they do not unreasonably chill opioid prescribing, denying patients pain 
treatment.  
 
Key informants from 34 of 40 countries said that doctors were hesitant to 
prescribe opioids because of fear of legal sanction for mishandling them, such as 
criminal sanctions or professional sanctions such as license revocation. Only key 
respondents from Thailand, France, Romania, Japan, Colombia, and Cameroon felt 
that healthcare workers have no fears of legal sanction sufficient to deter 
prescribing such medications. 
 
Cost of Opioid Medications 
Basic oral morphine in powder or tablet form is not protected by any patent and can be 
produced very cheaply. In India, basic morphine tablets are sold for as little as US$0.017 
                                                          
67 Human Rights Watch interviews with doctors in China, February, October, and November, 2010.  
68 International Narcotics Control Board, Demand for and Supply of Opiates for Medical and Scientific Needs, 15 (1989). 
69 See Chapter VII for more detail on governments’ obligation under the right to health to ensure that regulation of morphine 
prescribing does not unreasonably make pain medicines unavailable under the right to the highest available standard of health. 
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or about US$0.12 for a typical daily dose.70 Yet, the actual cost of morphine is much 
higher in many countries due to a variety of factors that drive up the price, including 
government regulation, licensing and taxation, poor distribution systems, low demand, 
large overhead of local production, and price regulation by some industrialized 
governments.71 In some countries, the promotion of non-generic and costly forms of 
opioid analgesics has resulted in pharmaceutical companies withdrawing inexpensive 
formulations.72 Paradoxically, morphine is often more expensive in low- and middle-
income countries than in industrialized countries.73  
 
The International Association for Hospice and Palliative Care recommends that “no government 
should approve modified release morphine … without also guaranteeing widely available 
normal release oral morphine.”74 Under the right to health, governments are obliged to ensure 
that both immediate release and slow release morphine tablets are available, as both are 
included in the WHO’s Model List of Essential Medicines.75 They must also explore ways to 
ensure that morphine is available at the lowest cost and is affordable to all people who need it, 
including by taking steps to ensure that government regulation does not disproportionately 
affect cost and considering subsidies for poor patients.76 
 
                                                          
70 Scott Burris & Corey S. Davis, A Blueprint for Reforming Access to Therapeutic Opioids: Entry Points for International 
Action to Remove the Policy Barriers to Care, Centers for Law and the Public's Health: A Collaborative at Johns Hopkins 
and Georgetown Universities, 2008, http://www.painpolicy.wisc.edu/internat/DCAM/Burris_Blueprint_for_Reform.pdf, 
(accessed November 2, 2010) p. 18; In low and middle-income countries a typical daily dose of morphine for patients in 
palliative care programs is 60 to 75 milligrams per day: Kathleen M. Foley et al., “Pain Control for People with Cancer and 
AIDS,” in Dean T Jamison et al., Disease Control Priorities in Developing Countries (Washington: World Bank Publications, 
2nd ed. 2003), pp. 981-994. The average daily dose in industrialized countries tends to be higher. This is due, among 
other reasons, to longer survival of patients and the development among patients of tolerance to opioid analgesics—
based on Human Rights Watch e-mail correspondence with Dr. Kathleen M. Foley, January 23, 2009.  
71 Liliana De Lima et al., “Potent Analgesics Are More Expensive for Patients in Developing Countries: A Comparative Study,” 
Journal of Pain and Palliative Care Pharmacotherapy, vol. 18, no. 1, (2004), p. 63.  
72 Ibid; David E. Joransen, M.R. Rajagopal and Aaron M. Gilson, “Improving Access to Opioid Analgesics for Palliative Care in 
India,” Journal of Pain and Symptom Management, vol. 24, no. 2 (2002), pp. 152-59.  
73 Liliana De Lima et al., “Potent Analgesics Are More Expensive for Patients in Developing Countries: A Comparative Study,” 
Journal of Pain and Palliative Care Pharmacotherapy, vol. 18, no. 1, (2004), p. 63.  
74 International Association for Hospice and Palliative Care, IAHPC List of Essential Medicines for Palliative Care, undated, 
http://www.hospicecare.com/resources/pdf-docs/iahpc-essential-meds-en.pdf (accessed November 2, 2010). 
75 UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the 
International Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable 
Standard of Health, E/C.12/2000/4 (2000), http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915 
005090be?Opendocument (accessed January 17, 2010), para. 43. 
76 See Chapter VIII for more detail on governments’ obligation to make pain medicines available under the right to the highest 
available standard of health. 
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Few of the healthcare workers surveyed were able to provide comprehensive information 
about the cost of morphine in their countries, but various healthcare workers did discuss the 
following matters:  
 
Availability of Expensive Formulations: Survey respondents in Bangladesh, Thailand, 
Ecuador, South Africa, and South Korea reported that inexpensive immediate release 
oral morphine was not available while more costly slow-release oral morphine 
tablets were. 
 
Subsidies: Subsidies can help ensure the affordability of pain medications. 
Survey respondents in Colombia, Egypt, Russia, and Uganda reported that their 
governments provide at least one formulation of morphine free of charge to all 
patients. Respondents from 13 countries –France, Georgia, China, Germany, Japan, 
Kenya, Mexico, Poland, Romania, South Africa, South Korea, Thailand, and the 
United Kingdom—said governments offered at least partial subsidies in some 
circumstances. In some of these countries, morphine was subsidized only for 
patients with low incomes or for hospital inpatients but not for outpatients, an 
approach that is inconsistent with WHO’s recommendation that countries 
prioritize developing home-based palliative care.77 In France, Georgia, Poland, and 
Romania, there are greater subsidies for cancer patients than other patients. This 
reflects the reality, discussed above, that WHO has made extensive 
recommendations on developing palliative care as part of cancer control programs 
but has said little about its importance for patients with other diseases.78 This 
approach could violate governments’ obligations to uphold the right to the 
highest attainable standard of health and specifically to provide essential 
medicines without discrimination on the basis of health status.79  
 
                                                          
77 World Health Organization, “National Cancer Control Programs: Policies and Managerial Guidelines,” 2002, 
http://www.who.int/cancer/media/en/408.pdf (accessed August 6, 2010), pp. 85, 91.  
78 World Health Organization, Cancer Pain Relief: a Guide To Opioid Availability, (2nd ed. 1996); World Health Organization, 
“National Cancer Control Programs: Policies and Managerial Guidelines,” 2002, 
http://www.who.int/cancer/media/en/408.pdf (accessed August 6, 2010), pp. 86. 
79 UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the 
International Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest 
Attainable Standard of Health, E/C.12/2000/4 (2000), 
http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915 
005090be?Opendocument (accessed January 17, 2010), paras. 18-19, 43.  
  
      25                Human Rights Watch | May 2011 
Best Practices: Addressing Barriers to Pain Treatment and Palliative Care 
through Comprehensive Reform  
In most low and middle-income countries, an assessment of barriers to access to 
morphine and the development of a plan of action must be the first step in a 
comprehensive effort to address those barriers. To be successful, reforms must address 
both supply and demand for morphine simultaneously; improving supply chains to 
increase morphine stocks will not improve patient access unless doctors are also 
adequately trained in pain treatment and palliative care, and vice-versa. In undertaking 
these reforms, governments can draw upon the expertise of the INCB and WHO. There are 
several nongovernmental organizations (NGOs) that work to improve the availability of 
medicines in developing countries, including Supply Chain Management Systems, the IDA 
Foundation, and Health Action International.80 On the whole, these NGOs have yet to turn 
their efforts to the availability of opioid pain medicines, but they have considerable 
relevant expertise that governments could draw upon.  
 
A number of countries have begun comprehensive reform efforts aimed at improving access 
to pain treatment and palliative care, with support from international organizations and have 
had some initial success. Such efforts in Uganda, Vietnam, Jordan, Colombia, and Romania 
are profiled in this report.  
                                                          
80 Supply Chain Management Solutions, http://scms.pfscm.org/scms (accessed December 1, 2010); IDA Foundation, 
http://www.idafoundation.org/we-are.html (accessed December 1, 2010); Health Action International, 
http://www.haiweb.org/ (accessed December 1, 2010). 
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Africa Map 
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III. Sub-Saharan Africa 
 
Table 2: Opioid Consumption and Percentage of Terminal Cancer and AIDS Patients Each 
Country Can Treat 
Country Annual Cancer and 
AIDS Deaths (2004) 
Estimated Number of Terminal Cancer and AIDS Patients Who 
Could be Treated with all 
Strong Opioids Consumed 
(2006-2008 Average) 
Are not Receiving Adequate 
Pain Treatment  
(minimum number) 
Could be Treated with all 
Strong Opioids 
Consumed (percentage) 
Angola 25,591 1,130 24,461 6.7% 
Benin 8,845 127 8,718 2.1% 
Botswana 16,777 348 16,429 4.0% 
Burkina Faso 20,705 58 20,647 0.4% 
Burundi 18,548 109 18,439 1.0% 
Cameroon 57,019 0 57,019 0.0% 
Cape Verde 259 70 189 33.9% 
Central African Republic 14,297 41 14,256 0.5% 
Chad 19,870 62 19,808 0.5% 
Comoros 324 0 324 0.0% 
Congo 9,909 84 9,825 1.5% 
Cote d'Ivoire 69,630 127 69,503 0.3% 
Democratic Republic of the Congo 121,311 832 120,479 1.1% 
Equatorial Guinea 1,576 Not reported Unknown Unknown 
Eritrea 4,278 82 4,196 3.0% 
Ethiopia 144,264 494 143,770 0.6% 
Gabon 4,142 0 4,142 0.0% 
Gambia 1,707 0 1,707 0.0% 
Ghana 37,766 1,976 35,791 8.4% 
Guinea 10,547 0 10,547 0.0% 
Guinea-Bissau 2,027 0 2,027 0.0% 
Kenya 164,048 4,035 160,014 4.6% 
Lesotho 17,585 128 17,458 1.4% 
Liberia 4,306 Not reported Unknown Unknown 
Madagascar 12,233 92 12,141 1.0% 
Malawi 83,467 415 83,052 0.9% 
Mali 15,568 41 15,527 0.4% 
Mauritania 2,700 94 2,606 4.7% 
Mauritius 1,019 8,042 0 994.8% 
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Country Annual Cancer and 
AIDS Deaths (2004) 
Estimated Number of Terminal Cancer and AIDS Patients Who 
Could be Treated with all 
Strong Opioids Consumed 
(2006-2008 Average) 
Are not Receiving Adequate 
Pain Treatment  
(minimum number) 
Could be Treated with all 
Strong Opioids 
Consumed (percentage) 
Mozambique 91,527 656 90,871 1.3% 
Namibia 11,081 855 10,225 14.7% 
Niger 15,274 79 15,196 0.7% 
Nigeria 285,434 247 285,187 0.1% 
Rwanda 27,174 45 27,130 0.3% 
Sao Tome and Principe 114 142 0 156.0% 
Senegal 11,309 96 11,213 1.1% 
Seychelles 93 57 37 77.5% 
Sierra Leone 8,028 53 7,975 1.0% 
South Africa 358,735 58,363 300,373 30.3% 
Swaziland 9,963 0 9,963 0.0% 
Togo 12,599 93 12,506 1.2% 
Uganda 121,789 4,877 116,913 7.4% 
United Republic of Tanzania 158,359 0 158,359 0.0% 
Zambia 91,383 674 90,708 1.4% 
Zimbabwe 190,720 1,365 189,356 1.4% 
 
Table Legend 
  GOOD AVAILABILITY: Most patients in pain are able to access treatment 
  SOME AVAILABILITY: Many patients in pain are unable to access treatment 
  LIMITED AVAILABILITY: Most patients in pain are unable to access pain treatment 
  VERY LIMITED AVAILABILITY: Few patients n pain are able to access treatment 
  SEVERE SHORTAGES: Very few patients are able to access treatment 
  Consumption of pain medicines is not reported 
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Regional Overview 
 
"Before I came [to Kenyatta National Hospital], I couldn't eat or breathe well 
[because of the pain]. Now that I have been given medicine [morphine], I can 
eat and breathe. I couldn't sit down, but now I can. I had pain for more than a 
month. I told the doctor and nurses [at another hospital] that I had pain. It 
took too long to get pain treatment… Here I got it immediately and started 
feeling well again." 
 – Christine L., an 18 year-old woman with Breast Cancer, Nairobi, Kenya. 
  
"We have no pethidine, no DF-118 (dihydrocodeine) and no morphine.... We 
have children here with advanced HIV; some are in severe pain. The pain 
management for children with advanced HIV is not enough." 
– Nurse, Bondo District Hospital, Kenya.   
 
Sub-Saharan Africa has the lowest consumption of opioid analgesics worldwide. As shown 
in Table 2, 37 sub-Saharan African countries consume so few opioid medications that even if 
they were used exclusively to treat pain in patients with terminal cancer and HIV, fewer than 
10 percent of those patients could receive adequate pain treatment. Eighteen countries 
could not treat even one percent of this group of patients, and eight countries reported no 
consumption of opioids at all during 2006 to 2008.  
  
Healthcare workers who must treat patients in facilities with no pain medications 
understandably express frustration. When Human Rights Watch visited a Kenyan hospital 
that had no opioid pain medicines a nurse showed us a child who had suffered severe burns, 
and said: “If we had diclofenac [a weak non-opioid pain reliever] we would give it, but we 
don’t have it here.”81 
 
Consequently, at least 1.2 million people in sub-Saharan Africa die from cancer or HIV/AIDS 
without adequate pain treatment each year. This is a very conservative estimate, which 
assumes that all opioids are used to treat this patient group. It should be considered merely 
an indicator of the enormous unmet need for pain treatment. In reality, the limited opioids 
that are available are used to treat patients suffering pain from other causes too.  So the real 
number of terminal cancer and HIV/AIDS patients with untreated pain must be higher, and 
                                                          
81 Human Rights Watch interview with head nurse, Bondo District Hospital, Kenya, March 1, 2010. 
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many other patients with non-terminal cancer and HIV/AIDS and with other diseases are also 
suffering untreated pain.  
 
While the challenging economic environment and poor health care infrastructure 
undoubtedly are a major reason for this situation, our survey findings suggest that 
government failure to take reasonable, low-cost steps to improve availability of opioid 
analgesics is a significant contributing factor in many countries.  
 
The African countries we surveyed have inadequate government policies to promote 
palliative care, inadequate medical education in pain treatment and palliative care, and 
very poor availability of morphine across different healthcare settings, indicating poor 
supply and distribution systems for opioids. African countries surveyed imposed few of the 
regulatory restrictions covered in this survey, but in all but one of the countries surveyed 
respondents reported that physicians’ fears about possible legal sanctions are a barrier to 
prescribing opioids. 
 
The survey findings highlight that even poor countries can make significant progress in 
delivering palliative care. Concerted efforts by Uganda’s government and civil society to 
improve access to palliative care have resulted in the removal of many of the barriers 
discussed in this survey. During 2006 to 2008 Uganda could already treat a significantly 
higher portion of its terminal HIV/AIDS and cancer patients than neighboring Kenya (Uganda: 
7.4 percent; Kenya: 4.6 percent), even though Kenya’s GDP is significantly higher than 
Uganda’s. The ongoing process of improving access to palliative care in Uganda, discussed 
below, means that Uganda’s consumption of opioids has likely increased subsequent to 
2008, so that more patients care receive treatment.  
 
Policy 
As Table 3 shows, there is little government support for palliative care in the seven African 
countries we surveyed, with Uganda the only country that has a national palliative care policy. 
Only two of the countries have cancer control policies that reference palliative care; four do not 
have such policies at all. Four countries surveyed had HIV policies that referred to palliative care 
but, despite high HIV/AIDS mortality levels, the HIV policies in three countries did not. More 
positively, most countries have included oral morphine in their essential medicines list 
although, as discussed below, it’s availability in practice is often very limited. 
 
Survey respondents from Ethiopia and Kenya reported that those countries are currently 
developing cancer control strategies. Kenya’s strategy is expected to include palliative care.  
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Table 3: Pain Treatment and Palliative Care Policies in Sub-Saharan Africa 
Country Palliative Care and Pain Management Policy Status of Morphine 
National 
Palliative Care 
Policy 
Reference in 
National Cancer 
Control Policy 
Reference in 
National AIDS 
Policy 
Oral Morphine a 
Registered 
Medicine 
Essential Medicines List 
Oral 
Morphine 
Injectable 
Morphine 
Ethiopia No N/A No Yes Yes Yes 
South Africa No Yes Yes Yes Yes Yes 
Tanzania No N/A Yes Yes No Yes 
Kenya No N/A No Yes Yes Yes 
Nigeria No Yes Yes Yes Yes Yes 
Cameroon No No No Yes Yes Yes 
Uganda Yes N/A Yes Yes Yes Yes 
 
Education 
The availability of education in pain management varied greatly in the African countries 
surveyed. As Table 4 shows, in three of the seven countries surveyed—Cameroon, 
Ethiopia, and Tanzania—no instruction in pain management is available at all for 
physicians. On the other hand, in Uganda, palliative care instruction is compulsory in all 
undergraduate medical programs and available in postgraduate medical education.  
 
Doctors from several of the African countries surveyed mentioned that some healthcare 
workers had received post-graduate education in palliative care from foreign institutions 
in other African countries and Europe through distance learning or programs run jointly 
between African and non-African institutions. This was the case in countries that had 
some domestic opportunities for post-graduate training, as well as those that did not. 
While these programs make an important contribution to building African expertise in 
palliative care, domestic programs are essential to adequately train sufficient numbers of 
healthcare workers in pain treatment and palliative care. 
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Table 4: Availability of Education in Pain Management in Sub-Saharan Africa  
Country Available in Undergraduate 
Medical Programs 
Compulsory in Undergraduate 
Medical Programs 
Available in Post-Graduate 
Medical Education 
Ethiopia None None No 
South Africa Most Some Yes 
Tanzania None None No 
Kenya All None Yes 
Nigeria Some Some Yes 
Cameroon None None No 
Uganda All All Yes 
 
Drug Availability 
Supply and Distribution  
Weak supply and distribution systems are a key reason for the low consumption of 
morphine in Africa. As Table 5 shows, respondents in all seven countries surveyed said 
that injectable morphine was not available in all hospitals, although it is available in 
most hospitals in Uganda and South Africa. While oral morphine is available at all tertiary 
hospitals in Kenya, South Africa, and Uganda, it is only available in some tertiary 
hospitals in Ethiopia, Nigeria, and Tanzania. In Africa, most health care is provided in a 
primary healthcare setting such as a health care center or clinics. In four countries 
surveyed, no health centers have oral morphine. In two countries, even hospices do not 
have oral morphine. Overall, availability of morphine was best in South Africa and Uganda 
and worst in Ethiopia and Cameroon.82 
 
While all countries surveyed have some availability of oral morphine, many other African 
countries do not. According to Anne Merriman, founder of Hospice Africa Uganda, several 
dozen countries in sub-Saharan Africa, including all 31 Francophone countries except 
Cameroon, do not have this essential medicine.83  
                                                          
82 Note that we asked what facilities usually stock morphine. Stock-outs are common in many African countries. In 2010, 
Kenya and Uganda both faced interruptions of morphine supply.  
83 Email correspondence with Anne Merriman, director of policy and international programs, Hospice Africa Uganda, June 22, 2010.  
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Table 5: Accessibility of Morphine in Different Healthcare Settings in Sub-Saharan Africa 
Country Injectable 
Morphine 
in Hospitals 
Accessibility of Oral Morphine 
Tertiary 
Hospitals 
Other Hospitals Pharmacies Health Centers Hospices AIDS Clinics 
Ethiopia Few Some None Some None None None 
South Africa Most All Most Most Most Most Most 
Tanzania Some Some Some None None Some Some 
Kenya Some All Some Few None All None 
Nigeria Some Some Some Some Some Some Some 
Cameroon Some Most Some None None None None 
Uganda Most All Most Few Few All Some 
 
Drug Regulations 
Our survey found relatively few restrictive drug regulations in African countries surveyed. None 
of the countries surveyed impose arbitrary dose limits on prescriptions or restrict prescribing 
rights to certain types of physicians. None of the countries require a special license for 
physicians to be allowed to prescribe opioid medications; although Ethiopian drug legislation 
in a UNODC database states a special license is required, survey respondents said the 
provision is not enforced in practice.84 Only two of the seven countries, Ethiopia and Cameroon, 
require a special prescription form. Cameroon and South Africa cap the number of days a 
prescription for opioid medications can cover at 30 days; other countries surveyed did not 
impose any limit. Key informants from Tanzania reported that while the country’s regulations do 
not require a special prescription form or impose a limit on the time that prescriptions can cover, 
some individual medical institutions do impose these.  
 
While our survey found few regulatory barriers, key informants from all African countries 
surveyed except for Cameroon reported that healthcare workers fear legal sanctions for 
prescribing opioid medications and identified this fear as a barrier to prescribing them.  
 
Although Uganda is leading the world by developing a program to train nurses to prescribe 
opioids, most of the African countries surveyed still do not allow nurse-prescribing. Because of 
low numbers of doctors and large populations living great distances from the nearest doctor or 
unable to afford the transport to travel to a doctor that is relatively close, allowing trained 
nurses to prescribe morphine is essential for increasing access to opioids in Africa. At present, 
                                                          
84 Proclamation No. 176/1999 a Proclamation to provide for Drug Administration and Control, s 26(1) available at United 
Nations Office of Drugs and Crime Legal Library: 
http://www.unodc.org/enl/showDocument.do?documentUid=2720&country=ETH (accessed January 13, 2011).  
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only Uganda allows specially trained nurses and clinical officers to prescribe morphine. South 
Africa is considering changing its regulations to allow nurses to prescribe. Human Rights Watch 
researchers have previously learned that nurses in some African countries give patients opioids 
when no doctor is available to do so, although this is contrary to the law. 
 
Table 6: Restrictive Regulation of Morphine Prescribing in Sub-Saharan Africa  
 
Cost 
Most of the African countries surveyed use oral liquid mixed from morphine powder, which 
can be prepared for just a few cents per dose. Nonetheless, for many Africans who subsist 
on less than US$1 per day, the cost remains prohibitive. Healthcare workers reported that 
many hospices and hospitals subsidize the cost of morphine for all their patients or for their 
poorest patients. The Ugandan government’s comprehensive effort to improve access to 
palliative care has included providing morphine free-of-charge.  
 
Doctors in Tanzania reported that weak supply chains make the real cost of providing 
morphine a burden upon health care services, because staff must travel long distances to 
collect oral morphine solution, incurring travel expenses and lost staff time. When they are 
available, other morphine formulations are often significantly more expensive than the 
lowest price at which they can be purchased internationally, probably due to low demand 
and weak supply chains.  
 
Best Practice and Reform Efforts: Uganda 
In the last 10 years, Uganda has led the African continent in efforts to improve access to 
palliative care, making significant progress on a number of fronts. The Ugandan government 
Country Prohibition on 
Prescribing 
Morphine for 
Home Use 
Morphine 
Prescription 
Form Differs 
from Regular 
Forms 
Signature of 
More Than 
One Doctor 
Required 
Right to Prescribe 
Morphine Limited 
to Doctors in 
Certain 
Specialties 
Special 
License 
Required to 
Prescribe 
Morphine 
Limitation on 
Length of 
Morphine 
Prescription 
Dose Limits 
Ethiopia No Yes No No Yes No No 
South Africa No No No No No 30 days No 
Tanzania No No No No No No No 
Kenya No No No No No No No 
Nigeria No No No No No No No 
Cameroon No Yes No No No 30 days No 
Uganda No No No No No No No 
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has worked with WHO and religious and nongovernmental organizations to systematically 
address barriers to access to palliative care.  
 
In its five-year Strategic Health Plan for 2000-2005, Uganda became the first African country 
to state that palliative care was an essential clinical service for all citizens. Since then, the 
government has worked to improve the availability of narcotic medications. It added liquid 
morphine to its essential drug list and adopted a new set of Guidelines for Handling of Class 
A Drugs for health care practitioners, also a first in Africa. The Ministry of Health also started 
importing oral morphine powder and providing oral morphine solution to public health 
facilities at no cost. Since 2000 opioid consumption in morphine equivalence has increased 
four-fold from less than 0.2 mg per person to almost 0.8 mg per person in 2008.85 
 
The government’s efforts have not been limited to improved drug provision. In 2004 
Ugandan law was amended to allow nurses and clinical officers, once they have completed a 
nine-month palliative care course, to prescribe morphine.86 More than 80 nurses and clinical 
officers have since graduated from Hospice Africa Uganda’s Clinical Palliative Care Course. 
In its 2004 report the INCB commended Uganda’s efforts to improve access to pain 
treatment, including reforming Uganda’s narcotics control laws so that specially trained 
nurses could prescribe morphine.87  
 
In recent years, Uganda has significantly boosted its capacity for palliative care. There are 
now at least 50 facilities providing palliative care services, including morphine.88 In order to 
reach more patients in need, community services for home-based palliative care have been 
greatly strengthened. The current strategic plan states that all hospitals and health centers 
should provide palliative care, that necessary medicines should be available, and that 
palliative care should be integrated into the curriculum of health training institutions. It also 
emphasizes the need to strengthen referral systems and community-based palliative care.89  
 
Uganda’s significant progress demonstrates the potential for government leadership to 
rapidly scale up access to palliative care through reforming laws and regulations, increasing 
drug provision, and encouraging education in palliative care. Many of the Ugandan 
                                                          
85 International Narcotics Control Board, “Narcotic Drugs: Estimated World Requirements for 
2010: Statistics for 2008,” 2010, http://www.incb.org/incb/en/narcotic_drugs_reports.html (accessed 27 October 2010). 
86 Jagwe and Merriman, “Uganda: Delivering Analgesia in Rural Africa,” Journal of Pain and Symptom Management. 
87 INCB, Report of the International Narcotics Control Board for 2004 (New York: United Nations, 2005), pp. 32-33.  
88 Palliative Care Association of Uganda (PCAU), “Audit Report of Palliative Care Services in Uganda,” April 2009, 
http://www.theworkcontinues.com/document.asp?id=1386&pageno= (accessed March 27, 2010), pp. 7 and 12.  
89 Jack Jagwe and Anne Merriman, “Uganda: Delivering Analgesia in Rural Africa: Opioid Availability and Nurse-prescribing,” 
Journal of Pain and Symptom Management, vol. 33, no. 5 (May 2007); Stjernsward, “Uganda: Initiating a Government Public 
Health Approach to Pain Relief and Palliative Care,” Journal of Pain and Symptom Management. 
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government’s reforms were carried out in cooperation with NGO representatives and WHO. 
Government, NGO, and WHO representatives met at a conference to discuss drug treatment 
availability in 1998, where they made commitments to taking specific measures to improve 
drug treatment availability. These plans and commitments have translated to many of the 
country’s achievements today.90  
 
Despite progress, many challenges remain in ensuring access to palliative care throughout 
Uganda. Some of the nurses trained in palliative care are not using their training because 
morphine is not available where they work or because hospital administrators are not 
supporting their efforts, for example, by failing to assign them to care for patients with life-
limiting disease. District health departments do not have defined palliative care budgets 
and inadequate distribution systems for morphine remain a problem.91 There is an ongoing 
need to ensure the availability of oral morphine throughout Uganda; to keep it affordable; 
prevent stock-outs; and train all relevant healthcare workers. 
                                                          
90 Jan Stjernsward, “Uganda: Initiating a Government Public Health Approach to Pain Relief and Palliative Care,” Journal of 
Pain and Symptom Management, vol. 24, no. 2 (August 2002).  
91 PCAU, “Audit Report of Palliative Care Services in Uganda,” p. 8. 
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IV. The Americas 
 
Table 7: Opioid Consumption and Percentage of Terminal Cancer and AIDS Patients Each 
Country Can Treat 
Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of Terminal 
Cancer and AIDS Patients Who 
Could Be Treated with All Strong 
Opioids Consumed 
Estimated Minimum Number 
of Patients Who Are Not 
Receiving Adequate Pain 
Treatment 
Estimated Percentage of Terminal 
Cancer and AIDS Patients Who 
Could Be Treated with All Strong 
Opioids Consumed 
Antigua and Barbuda 150 0 150 0.0% 
Argentina 64,674 65,277 0 127.5% 
Bahamas 508 609 0 174.4% 
Barbados 499 964 0 255.6% 
Belize 278 Not reported Unknown Unknown 
Bolivia 13,921 0 13,921 0.0% 
Brazil 218,361 206,079 12,282 121.6% 
Canada 70,049 3,169,908 0 5670.6% 
Chile 22,574 21,134 1,440 117.9% 
Colombia 42,396 40,055 2,342 124.4% 
Costa Rica 4,286 3,422 864 101.0% 
Cuba 19,282 4,770 14,512 31.0% 
Dominica 120 62 58 67.4% 
Dominican Republic 15,529 1,256 14,274 11.4% 
Ecuador 12,978 2,681 10,297 26.8% 
El Salvador 5,819 3,005 2,814 70.9% 
Grenada 174 84 90 62.9% 
Guatemala 10,945 2,102 8,844 25.8% 
Guyana 1,275 92 1,183 11.0% 
Haiti 14,569 68 14,501 0.8% 
Honduras 8,122 0 8,122 0.0% 
Jamaica 4,577 1,147 3,430 34.7% 
Mexico 80,175 62,110 18,065 99.2% 
Nicaragua 4,188 920 3,268 28.1% 
Panama 3,604 1,614 1,991 61.6% 
Paraguay 5,914 683 5,231 15.0% 
Peru 37,043 6,031 31,012 21.3% 
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Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of Terminal 
Cancer and AIDS Patients Who 
Could Be Treated with All Strong 
Opioids Consumed 
Estimated Minimum Number 
of Patients Who Are Not 
Receiving Adequate Pain 
Treatment 
Estimated Percentage of Terminal 
Cancer and AIDS Patients Who 
Could Be Treated with All Strong 
Opioids Consumed 
Saint Kitts and Nevis 55 Not reported Unknown Unknown 
Saint Lucia 200 192 7 122.1% 
Saint Vincent and the 
Grenadines 
173 63 110 51.2% 
Suriname 595 73 522 17.1% 
Trinidad and Tobago 2,064 1,012 1,052 69.7% 
United States of 
America 
617,820 31,797,701 0 6488.8% 
Uruguay 8,156 2,939 5,217 45.4% 
Venezuela 20,808 8,073 12,735 49.9% 
 
Table Legend 
  GOOD AVAILABILITY: Most patients in pain are able to access treatment 
  SOME AVAILABILITY: Many patients in pain are unable to access treatment 
  LIMITED AVAILABILITY: Most patients in pain are unable to access pain treatment 
  VERY LIMITED AVAILABILITY: Few patients n pain are able to access treatment 
  SEVERE SHORTAGES: Very few patients are able to access treatment 
  Consumption of pain medicines is not reported 
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Regional Overview 
 
"Cancer is killing us. Pain is killing me because for several days I have been 
unable to find injectable morphine in any place. Please, Mr.  Secretary of 
Health, do not make us suffer any more." 
– A classified ad placed in El País newspaper in Cali, Colombia, on 
September 12, 2008, by the mother of a woman with cervical cancer. 
 
"[In the United States there is a] widely publicized chilling effect of physician 
prosecution on physicians concerned with legal scrutiny over prescribing 
opioids…regulators and law enforcement may do well to improve how they 
craft their public messages to physicians and how they handle routine 
investigations of medical practice.” 
– Goldenbaum et al., "Physicians Charged with Opioid Analgesic-Prescribing 
Offenses," Pain Medicine, vol. 9, no. 6, 2008. 
 
Consumption of opioid analgesics varies greatly in the Americas from some of the highest 
levels in the world in the United States and Canada to very low levels in Central America and 
the Caribbean. At least 100,000 terminal cancer and HIV/AIDS patients die without adequate 
pain treatment in the Americas each year, although the real number is probably much higher.  
 
In Central America and the Caribbean, about half of the countries consume so few opioid 
medications that even if all were used exclusively to treat patients with terminal cancer and 
HIV for pain, less than a third of them could receive adequate treatment (Belize, El Salvador, 
Honduras, Nicaragua, Saint Kitts and Nevis, Trinidad and Tobago, Jamaica, Dominican 
Republic, and Haiti). Bolivia, Antigua and Barbuda, and Honduras reported no consumption 
of opioids for 2006 to 2008, and Haiti could treat pain in less than 1 percent of its terminal 
cancer and HIV/AIDS patients.  
 
In South America, consumption levels are generally significantly higher than in Central 
America and the Caribbean countries, but still far lower than in North America or Western 
Europe. Several South American countries, such as Bolivia, Ecuador, Peru, and Suriname, 
significantly lag behind their neighbors. In these countries, even if all opioid medications 
were used exclusively to treat chronic pain, fewer than 40 percent of patients could be 
treated adequately. 
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Policy 
As Table 7 shows, policy support for palliative care is very limited in the countries surveyed in 
the Americas. Five of eight countries do not have national palliative care policies; survey 
participants in two countries that do have such policies, Argentina and Brazil, said that they are 
not implemented in practice.92 A positive exception is Mexico, which recently adopted a policy 
on management of terminal patients. None of the countries surveyed have HIV policies that 
refer to palliative care and only two countries, Brazil and Colombia, address pain management 
in their national cancer control policies. More positively, oral morphine is a registered medicine 
in all countries surveyed, and most have it on their essential medicines lists. 
 
Table 8: Pain Treatment and Palliative Care Policies in the Americas 
Country Palliative Care and Pain Management Policy Status of Morphine 
National 
Palliative Care 
Policy 
Reference in 
National Cancer 
Control Policy 
Reference in 
National AIDS 
Policy 
Oral Morphine 
a Registered 
Medicine 
Essential Medicines List 
Oral Morphine Injectable 
morphine 
Brazil Yes Yes No Yes Yes Yes 
Argentina Yes N/A No Yes Yes Yes 
Colombia No Yes N/A Yes Yes Yes 
USA No N/A N/A Yes N/A N/A 
Mexico Yes 
Conflicting 
responses 
No Yes 
Conflicting 
responses 
Conflicting 
responses 
El Salvador No No No Yes Yes Yes 
Ecuador No No No Yes Yes Yes 
Guatemala No 
Conflicting 
responses 
No Yes Yes Yes 
 
Education 
Availability of undergraduate education in pain management and palliative care is very scarce 
in the countries surveyed in the Americas. In two countries, Mexico and El Salvador, instruction 
on palliative care is altogether unavailable in undergraduate programs, while in most other 
countries it is available only in a few or some such programs. Instruction on palliative care is 
compulsory only in some undergraduate medical programs in the United States and in a few in 
Guatemala. All of the region’s larger countries have opportunities for post-graduate medical 
                                                          
92 Human Rights Watch email correspondence with Dr Roberto Wenk, Argentina, October 18, 2010; Human Rights Watch email 
correspondence with Dr Roberto Bettega, Brazil, December 10, 2010. 
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education in pain treatment or palliative care, but these are lacking in the less-populous 
countries, such as Guatemala and possibly El Salvador. 
 
Table 9: Availability of Education in Pain Management in the Americas 
Country Instruction in Pain Management 
Available in Undergraduate 
Medical Programs 
Compulsory in Undergraduate 
Medical Programs 
Available in Post-Graduate Medical 
Education 
Brazil Some None Yes 
Argentina Few None Yes 
Colombia Some None Yes 
USA Some Some Yes 
Mexico None None Yes 
El Salvador None None Conflicting responses 
Ecuador Few None Yes 
Guatemala Few Few No 
 
Drug Availability 
Supply and Distribution  
The United States, the country with by far the highest opioid consumption of countries 
surveyed, has the greatest availability of morphine across clinical settings, followed by 
Brazil. Guatemala had the poorest, with morphine available in only some pharmacies and 
tertiary hospitals. Throughout Latin America, only some pharmacies stock oral morphine. Its 
availability in health centers and HIV/AIDS clinics is even poorer. Survey respondents in all 
countries said that it is harder to access opioids outside major cities. 
 
Table 10: Accessibility of Morphine in Different Healthcare Settings in the Americas 
Country Injectable 
Morphine 
In Hospitals 
Oral Morphine Available 
Tertiary Hospitals Other Hospitals Pharmacies Health Centers Hospices AIDS Clinics 
Brazil Most Most Most Some Some All Some 
Argentina Some Some Uncertain Some None Most N/A 
Colombia Some Some Some Some Some N/A None 
USA All All All Most Some All Some 
Mexico Some Some Uncertain Some None Some None 
El Salvador Some Some Uncertain Some Some Some Uncertain 
Ecuador Most Some Uncertain Some None Most None 
Guatemala Some Some None Some None N/A None 
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Drug Regulations 
All countries surveyed in the Americas require special prescription forms and four require 
physicians to obtain a special license to be allowed to prescribe opioid medications. 
Guatemala, the country with the lowest opioid consumption of those surveyed, also imposed 
the most types of restrictive regulation, including dose limits. Most of the American 
countries surveyed, with the exception of the United States and El Salvador, also impose a 
limit on the number of days that a morphine prescription can cover. Five countries have a 
relatively generous 30-day limit. In Argentina, however, a prescription can cover just 10 days.  
In El Salvador, all doctors can prescribe a limited, one-time dose of opioids to treat acute 
pain, but a different prescription form is needed to prescribe opioids for chronic pain, and 
those prescriptions must be authorized by the secretary of the health facility and the chief of 
the narcotics control agency. Survey respondents from all countries except Colombia said 
that healthcare workers fear legal sanction for mishandling opioids and that this was a 
deterrent to prescribing them. None of the Latin American countries surveyed allows nurse-
prescribing. In most US states, some types of nurses can prescribe morphine. In a few states 
physician assistants or pharmacists can also prescribe but others impose dose limits.  
  
Table 11: Restrictive Regulation of Morphine Prescribing in the Americas  
 
Cost 
Key informants in four countries—Argentina, Brazil, Colombia, and Mexico—said that the 
government subsidizes the cost of morphine in some circumstances. In Colombia, 
inexpensive oral liquid morphine is available, but in most countries surveyed in South 
America, most available morphine formulations are much more expensive, priced up to 
Country Prohibition on 
Prescribing 
Morphine for 
Home Use 
Morphine 
Prescription 
Form Differs 
from Regular 
Forms 
Signature of 
More Than 
One Doctor 
Required 
Right to Prescribe 
Morphine Limited to 
Doctors in Certain 
Specialties 
Special 
License 
Required to 
Prescribe 
Morphine 
Limitation 
on Length 
of 
Morphine 
Prescription 
Dose Limits 
Brazil No Yes No No Yes 30 Days No 
Argentina No Yes No No No 10 Days No 
Colombia No Yes No No No 30 Days       No 
USA No Yes No No Yes No 
Some state 
laws do 
Mexico No Yes No No No 30 Days No 
El Salvador No Yes Yes No Yes No Yes 
Ecuador No Yes No No Yes 30 Days Yes 
Guatemala No Yes No No No 30 Days No 
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several dollars for a daily dose. In Ecuador, El Salvador, and Guatemala, the three countries 
with the lowest opioid consumption of those surveyed, inexpensive immediate release oral 
morphine is unavailable although costly sustained release tablets are, making the price of 
morphine unnecessarily high. 
 
Best Practice and Reform Efforts: Colombia  
In Colombia, intensive engagement between the government, NGOs, and academics has led 
to recent progress in improving access to palliative care and pain management services. In 
the last five years, the government has undertaken significant regulatory reforms to remove 
unnecessary barriers to accessing pain treatment and improve access to opioid medicines. 
In 2006 the government increased the maximum number of days allowed for the prescription 
of opioids from 10 to 30 days,93 easing access for patients who need opioid therapy for 
extended periods of time. Revised regulation for regional drug procurement has also been 
put in place with the aim of improving opioid availability. The new regulation mandates all 
32 Colombian states to have at least one place where opioids are guaranteed to be in stock 
at all times.94 Morphine consumption has increased following these efforts to improve 
availability. Between 2006 and 2009, the government reported a 42 percent increase in 
units of morphine sold.95 
 
Modest gains have also been made in the field of education. The country’s first mandatory 
course in palliative care for undergraduate medical students was implemented at the 
Universidad de la Sabana in Bogota and could serve as a model for other universities.96 
Continuing education for primary health workers in palliative care is also available to a 
limited extent.97  
 
Columbia’s progress has resulted from several years of close engagement between the 
government and national and international NGOs and academic institutions. In 2006 
members of the Universidad de la Sabana, the International Association for Hospice and 
Palliative Care, the Pain and Policy Study Group, and the University of Wisconsin developed 
an action plan for improving access to palliative care and pain management services in 
                                                          
93 Colombian Minister of Health 001478 Resolution of 2006, https://www.alcaldiabogota.gov.co/sisjur/normas/normal.jsp.old 
(accessed January 27, 2011). 
94 Leon, Marta et al. “Integrating palliative care in public health: The Colombian experience following an International Pain 
Policy Fellowship” http://www.painpolicy.wisc.edu/publicat/11pallmed/LeonIPPF2011.pdf (accessed April 24, 2011).  
95 Ibid. 
96 Ibid. 
97 Ibid. 
  
 
47 Human Rights Watch | May 2011 
Colombia and later organized a workshop with members of the governments and the private 
health sector to identify barriers to accessing palliative care and solutions to these 
barriers.98 These efforts have largely guided Columbia’s reform efforts.  
Though Colombia still has far to go in guaranteeing access to pain treatment and palliative 
care for all who need it, greater progress may be on the horizon. The inclusion of three new 
opioid formulations in the country’s essential medicines list is being debated by the 
Regulatory Commission of Health.99 In addition, a proposed law that would seek to improve 
access to controlled medicines, quality of palliative care services, and education for 
healthcare workers was drafted by two senators with input from several Colombian palliative 
care experts and organizations.100 At time of writing, the senate had discussed the Bill but 
not yet voted on it.101  
                                                          
98 Leon, Marta Ximena et al. Improving Availability of and Access to Opioids in Colombia: Description and Preliminary Results 
of an Action Plan for the Country.  
99 Ibid.  
100 Ibid. 
101 Congresso Visible, http://www.congresovisible.org/proyectos-de-ley/mediante-la-cual-se-regulan/1080/ (accessed April 
1, 2011).  
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The Middle East and North Africa Map 
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V. The Middle East and North Africa 
 
Table 12: Opioid Consumption and Percentage of Terminal Cancer and AIDS Patients Each 
Country Can Treat 
Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated No.  of Terminal Cancer and 
AIDS Patients Who Could be Treated 
with All Strong Opioids Consumed 
Estimated minimum No.  of 
Patients Who Are Not Receiving 
Adequate Pain Treatment 
Estimated %  of Terminal Cancer and 
AIDS Patients Who Could Be Treated 
with All Strong Opioids Consumed 
Afghanistan 22,443 Not reported Unknown Unknown 
Algeria 20,006 2,890 17,116 18.2% 
Bahrain 414 761 0 234.2% 
Djibouti 1,391 0 1,391 0.0% 
Egypt 45,720 11,342 34,377 31.1% 
Iran  48,269 1,243,749 0 3266.6% 
Iraq 25,395 755 24,640 3.7% 
Israel 10,048 8,030 148,101 1844.4% 
Jordan 3,731 5,025 0 168.9% 
Kuwait 635 1,317 0 260.1% 
Lebanon 3,418 2,411 1,007 89.9% 
Libya 3,226 1,891 1,335 76.3% 
Morocco 14,805 3,090 11,715 26.6% 
Oman 1,214 584 630 61.0% 
Pakistan 98,082 1,726 96,356 2.2% 
Qatar 228 484 0 286.6% 
Saudi Arabia 11,890 15,072 0 158.9% 
Somalia 8,172 Not reported Unknown Unknown 
Sudan 53,049 501 52,548 1.4% 
Syria 5,918 5,287 631 111.7% 
Tunisia 4,556 5,260 0 146.0% 
United Arab 
Emirates 
792 2,438 0 397.7% 
Yemen 11,527 586 10,942 6.4% 
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Table Legend 
  GOOD AVAILABILITY: Most patients in pain are able to access treatment 
  SOME AVAILABILITY: Many patients in pain are unable to access treatment 
  LIMITED AVAILABILITY: Most patients in pain are unable to access pain treatment 
  VERY LIMITED AVAILABILITY: Few patients n pain are able to access treatment 
  SEVERE SHORTAGES: Very few patients are able to access treatment 
  Consumption of pain medicines is not reported 
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Regional Overview 
 
"Doctors are fearful of everything to do with opioids."  
– Oncologist, Jordan. 
  
“[The prescription limitation of] seven days is not enough. It makes our work 
harder and forces patients to travel long distances to have access to 
morphine” 
 – Professor of Oncology, Morocco. 
 
The Middle East and North Africa region is characterized by vast differences in resources, 
containing some very poor and some very wealthy countries. These differences are clearly 
reflected in the availability of opioid analgesics. Four countries in the region—Iraq, 
Pakistan, Sudan, and Yemen—consume so few opioid medicines that even if all were 
used only to treat patients with terminal cancer and HIV/AIDS for pain, less than 10 
percent of those patients could receive adequate pain treatment. Afghanistan and 
Somalia do not report opioid consumption to the INCB, and Djibouti reported no 
consumption for 2006 to 2008.  
 
A number of oil-rich nations, such as Bahrain, Kuwait, Saudi Arabia, Qatar, and United Arab 
Emirates, also consume relatively few opioid medications. Iran stands out in the region for 
its high consumption of opioids, particularly methadone, but a significant proportion is used 
for treating drug dependence, not pain. In all, at least 180,000 patients in the region will die 
of cancer or HIV/AIDS each year without adequate pain treatment.  
 
Policy  
None of the countries surveyed from the region has a national palliative care policy, 
although survey respondents in Morocco expect one to be adopted soon. While the 
cancer control policies of four of the five countries surveyed include references to pain 
treatment or palliative care, HIV policies, where they exist, do not. Egypt and Iran are 
among just six of the forty countries surveyed that have not included oral morphine in 
their essential medicines list.102 In fact, Iran is one of two of the forty countries surveyed 
where oral morphine is not a registered medicine and thus not available at all. Although 
                                                          
102 A further three countries (the United States, the United Kingdom, and Germany) reported that they do not have an 
essential medicine list, and there were conflicting responses from survey respondents in Mexico.  
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an article in a peer-reviewed medical journal states that Iran’s cancer control policy 
covers palliative care, Iranian key informants we surveyed were unaware of this.103  
 
Table 13: Pain Treatment and Palliative Care Policies in the Middle East and North Africa 
 
Education 
As shown in Table 14, Egypt is the only country surveyed in the region to have any 
compulsory instruction on palliative care as part of undergraduate medical programs. 
Morocco and Jordan do not have any instruction on palliative care available in such 
programs. In Iran and Jordan, no post-graduate instruction on palliative care exists. 
 
Table 14: Availability of Education in Pain Management in the Middle East and North Africa 
 
Country Available in Undergraduate 
Medical Programs 
Compulsory in Undergraduate Medical 
Programs 
Available in Post-Graduate Medical 
Education 
Pakistan Few  None Yes 
Egypt Some Some Yes 
Iran Some None No 
Morocco None None Yes 
Jordan None None No 
 
Drug Availability 
Supply and Distribution  
While injectable morphine is available in most or all hospitals in Egypt, Iran, and Morocco, 
this is only the case in some hospitals in Jordan and Pakistan. The availability of oral 
                                                          
103 “Implementation of Comprehensive National Cancer Control Program in Iran: an experience in a developing country” 
Annals of Oncology, Vol. 19, No.2, February 2008. p. 399.  
Country Palliative Care and Pain Management Policy Status of Morphine 
National 
Palliative Care 
Policy 
Reference in 
National Cancer 
Control Policy 
Reference in 
National AIDS 
Policy 
Oral Morphine a 
Registered 
Medicine 
Essential Medicines List 
Oral Morphine Injectable 
morphine 
Pakistan No No No Yes Yes Yes 
Egypt No Yes Uncertain Yes No Yes 
Iran No Yes No No No Yes 
Morocco No Yes N/A Yes Yes Yes 
Jordan No Yes No Yes Yes Yes 
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morphine is particularly poor in the countries surveyed in the region. As mentioned above, in 
Iran it is altogether unavailable. In Pakistan, oral morphine is not available in any hospices 
and only in few pharmacies and health centers. In Jordan, while available in all hospices, no 
health centers have morphine and only few pharmacies. Of the countries surveyed, Egypt 
has the best availability of oral morphine, with the medication available in all hospices, 
most tertiary hospitals, and some pharmacies and health centers. Survey respondents from 
all countries surveyed said that it is harder to access morphine outside of major cities. 
 
Table 15: Accessibility of Morphine in Different Healthcare Settings in the Middle East and 
North Africa 
 
Drug Regulations 
All countries surveyed in the region, except Pakistan, require special prescription forms for 
morphine. Survey respondents in Pakistan reported that some hospitals require the use of special 
prescription forms, even though they are not legally required. Four of the countries surveyed have 
limits on the length of time that a prescription can cover, again, all but Pakistan. In Iran, the limit is 
relatively generous at 30 days, but there are much shorter limits in Egypt (7 days), Jordan (10 days 
for cancer, 3 days for other patients), and Morocco (7 days).  
 
Regulations also restrict who can prescribe morphine and to whom. In Iran, morphine can 
only be prescribed for home use for cancer patients. In Egypt, most doctors can only 
prescribe up to 14 morphine tablets. Only oncologists and pain specialists can prescribe 
more. In Morocco, general practitioners must obtain a license to prescribe morphine, while 
other doctors working in hospitals or larger clinics are covered by that facility’s license. In all 
of the counties surveyed, at least one respondent felt that fear of legal sanction was a 
deterrent to prescribing opioids. None of the countries surveyed allow nurse prescribing. 
 
Country Injectable 
Morphine 
In Hospitals 
Oral Morphine Accessibility 
Tertiary 
Hospitals 
Other 
Hospitals 
Pharmacies Health 
Centers 
Hospices AIDS Clinics 
Pakistan Some Some Few  Few  Few  None None 
Egypt Most Most Some Some Some All N/A 
Iran All None None None None None None 
Morocco Most Some Few Some None N/A None 
Jordan Some Some Few Few None All N/A 
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Table 16: Restrictive Regulation of Morphine Prescribing in the Middle East and North Africa 
 
Cost 
In the Middle East and North Africa, poor accessibility does not appear to be attributable to 
the cost of morphine. Respondents in all those countries surveyed reported that the 
morphine formulations available are generally inexpensive.  
 
Developing Palliative Care: Jordan 
Jordan is one country in this region that has made significant strides in the last decade in 
developing palliative care. Between 2001, when the reform efforts began, and 2008, the last 
year for which data is available, consumption of morphine increased 2.5 times. In 2004 the 
Jordanian government partially reformed drug regulations, removing a provision that limited 
morphine prescribing rights to oncologists and slightly increasing the number of days a 
prescription for cancer patients can cover from 3 to 10 days (although it remains 3 days for 
non-cancer patients). That same year, a local pharmaceutical company began producing low 
cost immediate release morphine tablets, leading to a significant decline in the costs of the 
medication and an increase in the number of formulations available.104 
 
Although there is still no instruction on palliative care available in undergraduate or post-
graduate medical programs in Jordan, some progress has been made in educating health 
professionals. Through international fellowships, a handful of physicians have received in-
                                                          
104 Jan Stjernswärd et al., “Jordan Palliative Care Initiative: A WHO Demonstration Project,” Journal of Pain and Symptom 
Management, vol. 33, no. 5 (2007), p. 631. 
Country Prohibition on 
Prescribing 
Morphine for 
Home Use 
Morphine 
Prescription Form 
Differs from 
Regular Forms 
Signature of 
More Than 
One Doctor 
Required 
Right to Prescribe 
Morphine Limited 
to Doctors in 
Certain Specialties
Special License 
Required to 
Prescribe 
Morphine 
Limitation on 
Length of 
Morphine 
Prescription 
Dose 
Limits 
Pakistan No No No No No No No 
Egypt No Yes No Yes No 7 days 14 tablets 
Iran 
Yes (except for 
cancer 
patients) 
Yes No No No 30 days No 
Morocco No Yes No  No Yes 7 Days No 
Jordan No Yes No No No 
10 days for 
cancer patients; 
3 days for non-
cancer patients 
No 
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depth training. These physicians are now conducting palliative care training in other major 
oncology units in Amman and elsewhere.105 
 
Jordan’s progress demonstrates how much is possible with government leadership and a 
coordinated effort by government agencies, healthcare workers, UN agencies, and civil society. 
 
In 2001 the Jordanian government, WHO, healthcare workers, civil society, and the 
pharmaceutical industry came together and decided to establish the Jordan Palliative Care 
Initiative (JCPI), which was tasked with developing palliative care in the country and was 
designated a WHO Demonstration Project.106 In November that year, the Jordanian Ministry of 
Health and WHO agreed to work together to better integrate palliative care into the Jordanian 
health system.107 This lead to a joint workshop in 2003 to develop a national action plan and 
a National Palliative Care Committee.108  
 
These achievements should embolden Jordan’s government to raise palliative care 
availability to the next level by developing and implementing a national palliative care policy, 
expanding availability of morphine to more health facilities, further reforming its drug 
regulations, and introducing palliative care instruction into undergraduate and postgraduate 
medical and nursing curricula. 
 
                                                          
105 Amanda Bingley and David Clark, “A Comparative Review of Palliative Care Development in Six Countries Represented by 
the Middle East Cancer Consortium (MECC),” Journal of Pain and Symptom Management, vol. 37, no. 3 (2009) p. 291. 
106 Jan Stjernswärd et al., “Jordan Palliative Care Initiative: A WHO Demonstration Project,” Journal of Pain and Symptom 
Management, vol. 33, no. 5 (2007), p. 629. 
107 Ibid., p. 630 
108 Ibid. 
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Europe Map 
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VI. Europe 
 
Table 17: Opioid Consumption and Percentage of Terminal Cancer and AIDS Patients Each 
Country Can Treat 
Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of 
Terminal Cancer and 
AIDS Patients in 
Moderate to Severe 
Pain 
Estimated Number of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Estimated Minimum 
Number of Patients 
Who Are Not 
Receiving Adequate 
Pain Treatment 
Estimated Percentage of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Albania 4,604 3,680 2,526 1,154 68.6% 
Andorra 195 155 718 0 464.4% 
Armenia 6,549 5,217 599 4,618 11.5% 
Austria 19,701 15,744 513,347 0 3260.7% 
Azerbaijan 7,987 6,387 1,372 5,016 21.5% 
Belarus 20,076 15,821 2,854 12,967 18.0% 
Belgium 29,540 23,611 552,415 0 2339.6% 
Bosnia and 
Herzegovina 
6,201 4,957 20,424 0 412.0% 
Bulgaria 16,422 13,131 41,054 0 312.7% 
Croatia 12,585 10,067 82,780 0 822.3% 
Cyprus 974 779 1,782 0 228.8% 
Czech Republic 29,645 23,715 98,090 0 413.6% 
Denmark 16,012 12,800 413,601 0 3231.1% 
Estonia 3,634 2,900 12,038 0 415.0% 
Finland 10,703 8,560 154,722 0 1807.6% 
France 170,195 135,810 1,734,086 0 1276.8% 
Georgia 3,894 3,114 4,980 0 159.9% 
Germany 215,312 172,086 5,300,362 0 3080.1% 
Greece 27,535 22,023 169,908 0 771.5% 
Hungary 32,904 26,319 99,931 0 379.7% 
Iceland 565 452 7,326 0 1622.5% 
Ireland 9,101 7,272 190,643 0 2621.7% 
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Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of 
Terminal Cancer and 
AIDS Patients in 
Moderate to Severe 
Pain 
Estimated Number of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Estimated Minimum 
Number of Patients 
Who Are Not 
Receiving Adequate 
Pain Treatment 
Estimated Percentage of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Italy 163,308 130,381 1,104,943 0 847.5% 
Kazakhstan 24,125 19,220 2,293 16,926 11.9% 
Kyrgyzstan 4,203 3,356 5,927 0 176.6% 
Latvia 5,873 4,694 7,453 0 158.8% 
Lithuania 7,796 6,234 16,601 0 266.3% 
Luxembourg 1,039 830 15,043 0 1812.9% 
Macedonia 3,659 2,926 13,189 0 450.8% 
Malta 749 598 7,601 0 1270.4% 
Moldova 5,579 4,455 1,877 2,578 42.1% 
Monaco 71 56 Not reported Unknown Unknown 
Netherlands 41,463 33,142 507,144 0 1530.2% 
Norway 11,652 9,314 191,312 0 2054.1% 
Poland 96,802 77,399 273,683 0 353.6% 
Portugal 25,687 20,322 302,407 0 1488.1% 
Romania 43,315 34,577 15,936 18,641 46.1% 
Russia 287,330 226,189 34,894 191,295 15.4% 
San Marino 86 69 Not reported Unknown Unknown 
Serbia and 
Montenegro 
23,205 18,546 39,127 0 211.0% 
Slovakia 11,840 9,471 60,043 0 634.0% 
Slovenia 5,492 4,393 73,617 0 1675.7% 
Spain 106,174 84,413 1,850,392 0 2192.1% 
Sweden 21,025 16,812 270,389 0 1608.3% 
Switzerland 16,817 13,414 470,536 0 3507.9% 
Tajikistan 2,661 2,096 58 2,037 2.8% 
Turkey 59,814 47,817 93,610 0 195.8% 
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Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of 
Terminal Cancer and 
AIDS Patients in 
Moderate to Severe 
Pain 
Estimated Number of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Estimated Minimum 
Number of Patients 
Who Are Not 
Receiving Adequate 
Pain Treatment 
Estimated Percentage of 
Terminal Cancer and AIDS 
Patients Who Could be 
Treated with All Strong 
Opioids Consumed 
Turkmenistan 3,081 2,449 149 2,300 6.1% 
Ukraine 98,524 75,795 21,675 54,120 28.6% 
United Kingdom 163,370 130,632 1,569,345 0 1201.3% 
Uzbekistan 11,652 9,299 1,184 8,115 12.7% 
 
Table Legend 
  GOOD AVAILABILITY: Most patients in pain are able to access treatment 
  SOME AVAILABILITY: Many patients in pain are unable to access treatment 
  LIMITED AVAILABILITY: Most patients in pain are unable to access pain treatment 
  VERY LIMITED AVAILABILITY: Few patients n pain are able to access treatment 
  SEVERE SHORTAGES: Very few patients are able to access treatment 
  Consumption of pain medicines is not reported 
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Regional Overview 
There is a clear pattern in opioid consumption in Europe: Western European countries all 
consume at least 10 times as many opioids as is necessary to treat their terminal cancer and 
HIV/AIDS patients; Eastern European countries consume less but generally several times 
more than is necessary to treat their terminal cancer and HIV/AIDS patients. 
 
A handful of Eastern European and Central Asian countries—Armenia, Azerbaijan, Belarus, 
Kazakhstan, Russia, Ukraine, and Uzbekistan—consume only enough opioids to treat less 
than 30 percent of their terminal cancer and HIV/AIDS patients. Two central Asian countries, 
Tajikistan and Turkmenistan, can treat less than 10 percent of these patients. As a result, at 
least 480,000 terminal cancer and HIV/AIDS patients die in Europe each year without access 
to adequate pain treatment.  
 
As mentioned, Western European countries all consume at least 10 times as many opioids as 
is necessary to treat their terminal cancer and HIV/AIDS patients, and some Western 
European countries—Austria, Denmark, Germany, and Switzerland—consume more than 
thirty times more. These medicines are necessary to treat the many other patients that suffer 
pain, and this demonstrates that comparing actual opioid consumption to that which is 
necessary to treat terminal cancer and HIV/AIDS patients only gives an indicator of a 
country’s relative ability to meet its patients’ needs for pain relief.  
 
In countries where most people have access to the medicines they need most of the time, 
consumption is much higher than that which is necessary to treat terminal cancer and HIV/AIDS 
patients. Countries who can treat only those patients (i.e. those that score around 100 percent in 
these tables, such as Chile, Costa Rica, Mexico, Syria, Lebanon, and Uzbekistan) still have a very 
long way to go to ensure all patients in need can access essential pain medicines.  
 
Our survey results indicate that the marked contrast between opioid consumption in Eastern 
and Western Europe is not solely attributable to differences in economic development or 
medical infrastructure. The Eastern European countries surveyed have fewer policies to 
support pain treatment and palliative care, fewer opportunities for education in pain 
management and palliative care, more restrictive regulation on prescribing, and poorer 
accessibility of morphine across a range of healthcare settings.  
 
Policy 
Governments in four of the nine countries surveyed in Europe provide strong policy support for 
palliative care: France, Poland, Turkey, and the United Kingdom all have national palliative 
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care policies and cancer control policies that include palliative care. The first three also have 
national HIV policies that reference palliative care. There has been recent progress in Georgia, 
where a national palliative care policy and a cancer policy that includes a palliative care 
development plan have been submitted to parliament for adoption, but the HIV policy makes 
no reference to palliative care. Other countries surveyed provide less policy support. Germany 
does not have a national palliative care policy nor a national cancer or HIV control policy or an 
essential medicines list. Romania, Russia, and Ukraine do not have national palliative care 
policies but do provide for palliative care in national cancer control plans. 
 
Ukraine stands out as the only country surveyed in Europe where oral morphine is not a 
registered medicine. Ukraine and Georgia are the only countries surveyed that have 
essential medicines lists but have not included oral morphine. 
 
Table 18: Pain Treatment and Palliative Care Policies in Europe 
Country Palliative Care and Pain Management Policy Status of Morphine 
National 
Palliative Care 
Policy 
Reference in 
National Cancer 
Control Policy 
Reference in 
National AIDS 
Policy 
Oral Morphine 
a Registered 
Medicine 
Essential Medicines List 
Oral Morphine Injectable 
Morphine 
Germany No N/A N/A Yes N/A N/A 
Romania No Yes No Yes Yes Yes 
Poland Yes Yes Yes Yes Yes Yes 
Turkey Yes Yes Yes Yes Yes Yes 
UK Yes Yes No Yes N/A N/A 
France Yes Yes Yes Yes Yes Yes 
Russia No Yes Uncertain Yes Yes Yes 
Ukraine No Yes Yes No No Yes 
Georgia No No No Yes No Yes 
 
Education 
The European countries surveyed have the most extensive availability of training in pain 
management of any region. In France, Poland, and the United Kingdom, training in palliative 
care is compulsory for all undergraduate medical students. In 2009 Germany introduced 
legislation that will make training in palliative care compulsory for all undergraduate medical 
students by 2014. In all other countries surveyed, with the exception of Russia, palliative 
care instruction was available in at least some undergraduate medical programs. In Russia 
  
 
 
 
Global palliative care 62   
such instruction is available only in a few such programs. Survey respondents from all 
countries said that training in palliative care is available in post-graduate medical education. 
 
Table 19: Availability of Education in Pain Management in Europe 
Country Available in Undergraduate 
Medical Programs 
Compulsory in Undergraduate Medical 
Programs 
Available in Post-Graduate 
Medical Education 
Germany Most Few  Yes 
Romania Some None Yes 
Poland All All Yes 
Turkey Some Some Yes 
UK All All Yes 
France All All Yes 
Russia Few  Few  Yes 
Ukraine Some Some Yes 
Georgia Some Some Yes 
 
Drug Availability 
Supply and Distribution 
Our survey findings show a large gap between availability of morphine in Western and 
Eastern Europe. Availability was best in France, Germany, and the United Kingdom, with 
oral and injectable morphine available in most or all hospitals and pharmacies. In Poland 
and Turkey, the medications are available in most or all hospitals but only in some 
pharmacies. Survey respondents in Romania and Russia said injectable morphine was 
available in most hospitals but oral morphine only in some hospitals and pharmacies. 
Georgia and Ukraine reported the most problematic situations, with oral morphine 
altogether unavailable in Ukraine and only available in some tertiary hospitals, 
pharmacies, and hospices in Georgia. In most countries surveyed, except Germany, 
Poland, and France, survey respondents reported that it is harder to access morphine 
outside of major cities.  
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Table 20: Accessibility of Morphine in Different Healthcare Settings in Europe 
Country Injectable 
Morphine 
In Hospitals 
Oral Morphine Available in 
Tertiary 
Hospitals 
Other 
Hospitals 
Pharmacies Health 
Centers 
Hospices AIDS Clinics 
Germany Most All Most Most Most All Uncertain 
Romania Most Some Some Some None All None 
Poland All All Most Some None All None 
Turkey All Most All Some Most N/A Conflicting 
Response 
UK All All All All Some All Uncertain 
France All All All All Few N/A All 
Russia All Some Some Some None Some Uncertain 
Ukraine Some None None None None None None 
Georgia All Some None Some None Some None 
 
Drug Regulations 
Significant differences between regulations in Western and Eastern Europe are apparent 
from the survey, with Georgia, Russia, and Ukraine imposing both greater numbers of and 
more severe restrictive prescription requirements than other countries surveyed. Four of five 
European Union countries require special prescription forms but do not impose other 
problematic regulatory restrictions. 
 
Turkey requires special prescription forms, as well as signatures from multiple doctors for 
long-term opioid prescriptions, and imposes a 200 mg daily dose limit for morphine, which 
is likely to be insufficient for significant numbers of patients. Georgia, Russia, and Ukraine 
require special prescription forms but doctors must also get special licenses to be allowed to 
prescribe morphine, and these counties impose low limits on the number of days a 
prescription can cover. Russia and Ukraine also require that multiple doctors sign 
prescriptions and impose limits on daily doses, with Ukraine’s limits particularly low, lower 
than the average daily dose for a patient with terminal cancer of HIV/AIDS.109 Georgia and 
Ukraine also limit the right of prescription of opioids to doctors in certain specialties, such 
as oncology. In all surveyed countries except Romania and France, survey respondents 
reported that fear of legal sanction deters prescribing of opioids. 
 
                                                          
109 Kathleen M. Foley et al., “Pain Control for People with Cancer and AIDS,” in Dean T Jamison et al., Disease Control Priorities 
in Developing Countries (Washington: World Bank Publications, 2nd ed. 2003), pp. 981-994; Germany imposes a limit of 
20,000mg per prescription, but this can be exceeded if the doctor marks the prescription in a specified manner.  
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Table 21: Restrictive Regulation of Morphine Prescribing in Europe  
 
Cost 
In most of the European countries surveyed, healthcare workers mentioned that the cost of 
morphine is fully or partially-subsidized by the government, but in several countries only 
cancer patients qualify for subsidies or subsidies are more generous for cancer patients.  
 
Best Practice and Reform Efforts: Romania 
Romania has taken significant steps in the last few years to revise laws and regulations in order 
to improve access and availability of pain treatment and palliative care in the country. New 
legislation from November 2006 and new regulations from May 2006 corrected imbalanced 
laws and regulations that had severely limited doctors’ authority to prescribe opioids in 
Romania. The new laws and regulations establish that it is the sole responsibility of the doctor 
to determine the appropriate opioid dose and allow doctors to prescribe opioids to patients in 
severe pain regardless of the underlying disease. Prior to the reforms, doctors could only 
prescribe opioids to patients suffering from a limited class of diseases, such as cancer in its 
advanced stages. Progress has also been made in ensuring the availability of a variety of opioid 
formulations in Romania, many of which are produced domestically. 
 
Country Prohibition 
on 
Prescribing 
Morphine for 
Home Use 
Morphine 
Prescription 
Form Differs 
from Regular 
Forms 
Signature of 
More Than 
One Doctor 
Required 
Right to 
Prescribe 
Morphine 
Limited to 
Doctors in 
Certain 
Specialties 
Special License 
Required to 
Prescribe 
Morphine 
Limitation on 
Length of 
Morphine 
Prescription 
Dose Limits 
Germany No Yes No No No No No 
Romania No Yes No No No 30 days No 
Poland No Yes No No No 30 days No 
Turkey No Yes Yes, for long 
term use 
No No No 200 mg 
UK No No No No No No No 
France No No No No No 28 days No 
Russia No Yes Yes No Yes 10 Days 200 mg per 
prescription for 
injectable 
morphine 
Ukraine No Yes Yes Yes Yes 10 Days 50 mg 
Georgia No Yes No Yes Yes 7 days No 
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The new regulations also provide for the improvement of Romanian health workers’ 
education in palliative care.110 The new regulations led Casa Sperantei, the first independent 
hospice in Romania, in Brasov, to offer courses in palliative care to health professionals, 
with the assistance of a grant from the Open Society Institute (OSI). Over 4,000 doctors have 
since completed this Ministry of Health-approved course. Although the Romanian Ministry of 
Health had identified palliative care as a “medical sub-specialty” in 2000, the medical 
profession had not received adequate training, and fear of prescribing opioids on the part of 
health professionals remains widespread. Increased and improved education in palliative 
care is a step towards addressing these barriers.  
 
Romania’s progress demonstrates what can be achieved through the combined efforts of 
local professionals, international experts, and national authorities.111 Reform efforts in 
Romania began with Romania’s participation in a 2002 workshop convened by OSI and WHO. 
Following an initial assessment and action plan for improving palliative care in Romania, 
Romania was selected as a pilot country by OSI and the Pain and Policy Studies Group 
(PPSG). In 2002, the Romanian Ministry of Health appointed a commission of specialists to 
provide reform recommendations. Working in collaboration with PPSG, the palliative care 
commission used WHO guidelines to present the Ministry of Health with a number of 
recommendations for the reform, many of which were incorporated into the country’s revised 
laws and regulations.  
 
Despite the impressive progress that has been made, substantial challenges remain in 
providing palliative care in Romania. Many hospitals continue not to stock morphine 
because it “is not included in the drug list for emergencies in acute hospitals.” This leads to 
reliance on pethidine, a weaker opioid that is not appropriate for treatment of chronic pain. 
Accessibility issues persist as the number of pharmacies stocking morphine, particularly in 
rural areas, remains inadequate. Many doctors in Romania are still hesitant to prescribe 
opioids, indicating that further education efforts are needed.112  
                                                          
110 Article 54 of the regulation. 
111 Daniela Mosoiu et al., “Romania: Changing the Regulatory Environment”, Journal of Pain and Symptom Management, vol. 
33, no. 5 (2007), p. 613. 
112 Human Rights Watch interview with Associate Professor Dr. Daniela Mosoiu, Romania, February 17, 2010. 
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Asia Map 
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VII. Asia 
 
Table 22: Opioid Consumption and Percentage of Terminal Cancer and AIDS Patients Each 
Country Can Treat 
Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of 
Terminal Cancer and 
AIDS Patients in 
Moderate to Severe 
Pain 
Estimated Number of 
Terminal Cancer and AIDS 
Patients who Could be 
Treated with All Strong 
Opioids Consumed 
Estimated Minimum 
Number of Patients who 
are not Receiving 
Adequate Pain 
Treatment 
Estimated Percentage of 
Terminal Cancer and AIDS 
Patients who Could be 
Treated with All Strong 
Opioids Consumed 
Australia 40,680 32,510 1,052,428 0 3237.2% 
Bangladesh 90,359 72,252 6,190 66,062 8.6% 
Bhutan 405 324 43 282 13.1% 
Brunei  209 167 117 50 70.3% 
Burma 63,646 44,225 1,928 42,296 4.4% 
Cambodia 21,669 14,277 91 14,186 0.6% 
China 1,849,527 1,473,317 779,984 693,333 52.9% 
Cook Islands 9 7 108 0 1537.4% 
North Korea 22,626 18,089 3,073 15,017 17.0% 
Fiji 458 362 Not reported Unknown Unknown 
India 905,132 684,084 81,046 603,039 11.8% 
Indonesia 203,127 162,413 24,628 137,784 15.2% 
Japan 322,008 257,591 387,341 0 150.4% 
Kiribati 33 27 0 27 0.0% 
Laos 4,238 3,383 139 3,244 4.1% 
Malaysia 24,655 19,103 105,319 0 551.3% 
Maldives 512 392 54 339 13.7% 
Marshall Islands 52 42 53 0 126.0% 
Micronesia  53 42 52 0 122.0% 
Mongolia 4,183 3,346 489 2,857 14.6% 
Nauru 9 7 51 0 743.1% 
Nepal 18,399 14,643 1,882 12,761 12.8% 
New Zealand 8,205 6,561 161,493 0 2461.3% 
Niue 1 1 Not reported Unknown Unknown 
Palau 12 10 216 0 2213.3% 
South Korea 83,994 67,169 149,967 0 223.3% 
Samoa 106 85 53 32 62.1% 
Singapore 5,636 4,488 3,796 692 84.6% 
Solomon Islands 185 147 0 147 0.0% 
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Table Legend 
  GOOD AVAILABILITY: Most patients in pain are able to access treatment 
  SOME AVAILABILITY: Many patients in pain are unable to access treatment 
  LIMITED AVAILABILITY: Most patients in pain are unable to access pain treatment 
  VERY LIMITED AVAILABILITY: Few patients n pain are able to access treatment 
  SEVERE SHORTAGES: Very few patients are able to access treatment 
  Consumption of pain medicines is not reported 
Country Annual Cancer 
and AIDS 
Deaths (2004) 
Estimated Number of 
Terminal Cancer and 
AIDS Patients in 
Moderate to Severe 
Pain 
Estimated Number of 
Terminal Cancer and AIDS 
Patients who Could be 
Treated with All Strong 
Opioids Consumed 
Estimated Minimum 
Number of Patients who 
are not Receiving 
Adequate Pain Treatment 
Estimated Percentage of 
Terminal Cancer and AIDS 
Patients who Could be 
Treated with All Strong 
Opioids Consumed 
Thailand 151,088 102,226 31,093 71,134 30.4% 
Timor-Leste 455 362 Not reported Unknown Unknown 
Tonga 61 48 53 0 108.5% 
Tuvalu 9 7 0 7 7.4% 
Vanuatu 113 90 77 13 49.9% 
Vietnam 81,801 61,640 17,477 44,163 6.4% 
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Regional Overview 
 
"My leg would burn like a chili on your tongue. The pain was so severe I felt 
like dying. I was very scared. I felt that it would be better to die than to have 
to bear this pain. [I thought], just remove the leg, then it will be alright. Just 
get rid of the leg so I'll be free of pain." 
- Dilawar Joshi, a Nepali man with a bone tumor, India 
 
"I would sleep maybe an hour and a half per night. I could take any number 
of sleeping pills [without effect]. With morphine, I can relax. This place [the 
palliative care unit] is heaven-sent..." 
- Shruti Sharma, Hyderabad, a breast cancer patient, India 
 
Consumption of opioids varies dramatically throughout Asia. Australia and New Zealand 
consume more than 20 times more opioids than are needed to treat their terminal cancer and 
HIV/AIDS patients. By contrast, Bhutan, North Korea, India, Indonesia, the Maldives, Mongolia, 
Nepal, and Sri Lanka can all treat less than 20 percent of their terminal cancer and HIV/AIDS 
patients, and Bangladesh, Burma, Cambodia, Laos, and Vietnam less than 10 percent. The 
Solomon Islands reported no consumption of opioids at all between 2006 and 2008.  
 
The world’s two most populous countries—India and China—can treat just 12 and 53 percent of 
their terminal cancer and HIV/AIDS patients respectively. Thus although Asia has better 
treatment coverage than sub-Saharan Africa, it also has the largest number of patients suffering 
without treatment of any region, at least 1.7 million terminal cancer and HIV/AIDS patients.  
 
Policy 
While nine of eleven countries surveyed reference palliative care in their national cancer 
control policies (Cambodia and Nepal are the exceptions) only four of eleven—Indonesia, 
Philippines, South Korea, and Vietnam—have national palliative care policies. Only three 
countries— Cambodia, Nepal, and Vietnam—provide for palliative care in national HIV 
policies. Oral morphine is a registered medicine in all the countries surveyed, and both oral 
and injectable formulations are on the essential medicines lists of all countries except South 
Korea. Vietnam stands out as the country that provides the best policy support for palliative 
care, with a national palliative care policy and palliative care provisions in its national 
cancer and HIV plans. 
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Table 23: Pain Treatment and Palliative Care Policies in Asia 
 Country Reference to Palliative Care and Pain Management Policy Status of Morphine 
National 
Palliative Care 
Policy 
Reference to Palliative 
Care in National 
Cancer Control Policy 
Reference to 
Palliative Care in 
National AIDS Policy 
Oral Morphine 
a Registered 
Medicine 
Essential Medicines List 
Oral Morphine Injectable Morphine 
India No Yes No Yes Yes Yes 
Bangladesh No Yes No Yes Yes Yes 
Thailand No Yes No Yes Yes Yes 
Nepal No No Yes Yes Yes Yes 
Indonesia Yes Yes No Yes Yes Yes 
Philippines Yes Yes No Yes Yes Yes 
Vietnam Yes Yes Yes Yes Yes Yes 
South Korea Yes Yes No Yes No No 
Japan No Yes No Yes Yes Yes 
China No  Yes No Yes Yes Yes 
Cambodia No N/A Yes Yes Yes Yes 
 
Education 
Availability of instruction on palliative care in undergraduate medical programs is poor in 
most countries in the region surveyed, with Bangladesh and Nepal, which both offer 
compulsory instruction on palliative care in most undergraduate medical programs, 
performing best. Palliative care instruction is available only in few undergraduate 
programs in India, Indonesia, and South Korea. In Cambodia, Philippines, South Korea, 
and Vietnam, no compulsory instruction in palliative care is available in any 
undergraduate medical programs. Key informants in most countries said that instruction 
on palliative care was available in post-graduate medical education, but in China such 
instruction is not available at all. 
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Table 24: Availability of Education in Pain Management in Asia 
 
Country Available in Undergraduate 
Medical Programs 
Compulsory in Undergraduate 
Medical Programs 
Available in Post-Graduate 
Medical Education 
India Few Few Yes 
Bangladesh Most Most Yes 
Thailand Most Some Yes 
Nepal Most Most Yes 
Indonesia Few Few Conflicting information 
Philippines Most None Yes 
Vietnam Some None Yes 
South Korea Few  None Yes 
Japan Most Some Yes 
China Some Some No 
Cambodia Some None Yes 
 
Drug Availability 
Key informants in Cambodia, China, Japan, and South Korea reported the widest 
availability of morphine, with the medication available in most or all hospitals. However, 
in Cambodia and China, oral morphine is not available at all in pharmacies and in few or 
no health centers, creating significant obstacles to its accessibility in rural areas. Poorest 
overall availability was reported in Bangladesh, where oral morphine is not at all 
available in hospitals and health centers and only in some pharmacies and few hospices 
in India, Nepal, Philippines, and Vietnam. In each of these countries oral and injectable 
morphine is available only in some hospitals, health centers, and pharmacies, although 
reported availability in hospices is slightly better. Doctors in all the countries surveyed in 
Asia reported that morphine is harder to access outside major cities.  
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Table 25. Accessibility of Morphine in Different Healthcare Settings in Asia 
Country Injectable 
Morphine 
In Hospitals 
Oral Morphine 
Tertiary 
Hospitals 
Other 
Hospitals 
Pharmacies Health 
Centers 
Hospices AIDS Clinics 
 
India Some Some Some Few Few Some None 
Bangladesh Some None None Some None Few None 
Thailand All Most Some Some Some All N/A 
Nepal Some Some Some Some None Most Few  
Indonesia Most Most Some Some Some N/A Most 
Philippines Some Some Some Some Some Most Some 
Vietnam Some Some Some Some None Some Some 
South Korea Most All Most Some None All All 
Japan All All Most Some None All All 
China Most All Most None Few  Most Most 
Cambodia Most All Most None None Most 
Conflicting 
Response 
 
Medicines Availability: Restrictive Regulation  
Of the 11 Asian countries surveyed, Cambodia has by far the most restrictive regulations. It 
prohibits prescribing of morphine for home use, requires doctors to get a special license to 
be allowed to prescribe morphine, requires multiple doctors to sign off on morphine 
prescriptions, and imposes a 7-day limit on the number of days a prescription can cover. 
 
Seven of the ten other Asian countries surveyed require a special prescription form for 
morphine—India, Indonesia, and Nepal are the exceptions—and three others, China, Japan, 
and Philippines, require doctors to obtain a special license before they can write such 
prescriptions. Regulations in four of the other ten countries imposed limitations on the 
number of days a prescription can cover. In Japan, Philippines, and Vietnam, the limit is a 
relatively generous 30 days. In China, it depends on the formulation of morphine: 15 days for 
sustained release, 7 days for immediate release, and 3 days for injectable morphine. Survey 
respondents in South Korea, where regulations do not impose such limit, said that many 
hospitals enforce their own limits, which are often as short as one week or even one day. In 
all but two of the countries surveyed in the region—Japan and Thailand—doctors reported 
that fear of legal sanction deters opioid prescribing.  
 
None of the countries surveyed in Asia allow nurse-prescribing, although Vietnam allows 
assistant doctors to prescribe morphine in remote areas (see below).  
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Table 26. Restrictive Regulation of Morphine Prescribing in Asia 
Country Prohibition on 
Prescribing 
Morphine for 
Home Use 
Morphine 
Prescription Form 
Differs from 
Regular Forms 
Signature of 
More Than 
One Doctor 
Required 
Right to Prescribe 
Morphine Limited 
to Doctors in 
Certain Specialties 
Special License 
Required to 
Prescribe 
Morphine 
Limitation on 
Length of 
Morphine 
Prescription 
Dose 
Limits 
India No No No No No No No 
Bangladesh No Yes No No No Uncertain No 
Thailand No Yes No No No 
Conflicting 
Response 
No 
Nepal No No No No No No No 
Indonesia No No No No No No No 
Philippines No Yes No No Yes 30 Days 
25000mg/
month 
Vietnam No Yes No No No 30 Days No 
South Korea No Yes No No No No No 
Japan No Yes No No Yes 30 Days No 
China No Yes No No Yes 
Yes – length 
varies 
No 
Cambodia Yes Yes Yes No Yes 7 days No 
 
Cost 
The cost of morphine varies markedly throughout the region. The price can be very 
inexpensive in countries that have domestic production of morphine, including India and 
Vietnam, and other countries, including Japan and China, subsidize its cost. In some 
countries, including Nepal, there is an official government price for morphine, but shortages 
mean the price on the black market is sometimes much higher.  
 
Developing Palliative Care: Vietnam 
Between 2005, when palliative care reforms began, and 2008, Vietnam saw an over 800 
percent increase in morphine equivalent consumption, from 0.3 mg per person to 2.5 mg per 
person.113 Vietnam has focused its reform efforts on removing unnecessary barriers to 
prescribing opioids and educating healthcare personnel in palliative care. In 2008 the country 
eased a number of key regulatory barriers to opioid prescription: the maximum daily opioid 
dose was abolished, prescriptions can now be issued for 30 days rather than 7, and district 
                                                          
113 Consumption Data. International Narcotics Control Board. 
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hospitals and commune health posts are now authorized to prescribe and dispense 
morphine.114 Assistant doctors in “mountainous, remote, island, disadvantage areas and places 
where a doctor is not available” are also now able to obtain a license to prescribe morphine.115  
 
New education programs and opportunities have also been developed. In 2008 the Ministry 
of Health piloted a certification program in palliative care and held a two-day workshop on 
new palliative care guidelines and regulations for more than 1,000 health care managers, 
pharmacists, and physicians from around the country.116 As of 2010, 400 Vietnamese doctors 
have completed a one-week curriculum in palliative care, developed with assistance from 
the Harvard Medical School Center for Palliative Care.117 Two Vietnamese medical colleges 
now offer instruction on palliative care to undergraduate medical and nursing students, and 
a National Curriculum in Palliative Care was expected to be published in 2010.118 
 
This progress started with the creation of a working group on palliative care, which consisted 
of Ministry of Health officials, cancer and infectious disease physicians, and experts from 
NGOs supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR). The working 
group decided to conduct a rapid situation analysis to assess the availability of and the 
need for palliative care in Vietnam.119 Based on the rapid situation analysis’s findings, the 
working group recommended that national palliative care guidelines and a balanced 
national opioid control policy be developed, training for healthcare workers be expanded, 
and that availability and quality of palliative care services be improved at all levels. In 
September 2006, the Ministry of Health issued detailed Guidelines on Palliative Care for 
Cancer and AIDS Patients, which provided guidance to practitioners on palliative care and 
pain management, and in February 2008, it issued new guidelines on opioid prescription, 
which eased regulatory barriers as described above.  
 
Despite this progress, numerous challenges remain in delivering palliative care in Vietnam. 
Attitudes toward, and an understanding of, palliative care among health care professionals 
continue to be limited and lag behind regulatory changes. Although morphine can be 
                                                          
114 While this is an improvement, patients and their families can only fill prescriptions for 10 days at a time, after which their 
local commune must confirm in writing that the patient is still alive. 
115 Human Rights Watch interview with Dr Eric Krakauer, November 3, 2009.  
116Eric L. Krakauer, Nguyen Thi Phuong Cham, Luong Ngoc Khue. Vietnam's Palliative Care Initiative: Successes and 
Challenges in the First Five Years. Journal of Pain and Symptom Management, 2010 40(1): 27-30. 
117Ibid. 
118 Human Rights Watch interview with Dr Eric Krakauer, November 3, 2009. 
119 Green K, Kinh LN, Khue LN., “Palliative care in Vietnam: Findings from a rapid situation analysis in five provinces,” (Hanoi: 
Vietnam Ministry of Health, 2006). 
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prescribed for 30 days, a prescription can only be filled for 10 days a time, after which point 
it must be confirmed that the patient is alive and using the medication appropriately.120 The 
availability of opioids continues to be limited, especially in rural areas, as few pharmacies 
and hospitals stock oral morphine. 
                                                          
120 Human Rights Watch interview with Dr. Eric Krakauer, November 3, 2009. 
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VIII. International Human Rights Obligations and Pain Treatment 
 
Health as a Human Right 
The right to the highest attainable standard of health is a fundamental human right 
enshrined in numerous international instruments.121 The International Covenant on Economic, 
Social and Cultural Rights (ICESCR) specifies that everyone has a right “to the enjoyment of 
the highest attainable standard of physical and mental health.”122 The Committee on 
Economic, Social and Cultural Rights (CESCR), the body charged with monitoring compliance 
with the ICESCR, has held that states must make available in sufficient quantity “functioning 
public health and health-care facilities, goods and services, as well as programmes” and 
that these services must be accessible.123 
 
Because states have different levels of resources, international law does not mandate the 
standard of health care to be provided. Rather, the right to health is considered a right of 
“progressive realization.” By becoming party to the international agreements, a state agrees 
“to take steps … to the maximum of its available resources” to achieve the full realization of 
the right to health. In other words, high income countries will generally have to provide 
healthcare services at a higher level than those with limited resources. But all countries will 
be expected to take concrete steps towards increased services, and regression in the 
provision of health services will, in most cases, constitute a violation of the right to health. 
The CESCR has held that states have a “specific and continuing obligation to move as 
expeditiously and effectively as possible towards the full realization” of the right to health 
and must “refrain from interfering directly or indirectly with [its] enjoyment.”124 
 
                                                          
121 International Covenant on Economic, Social and Cultural Rights (ICESCR), G.A. res. 2200A (XXI), 21 U.N.GAOR Supp. (No. 16) at 49, 
U.N. Doc. A/6316 (1966), 993 U.N.T.S. 3, entered into force January 3, 1976, art. 11; See also Convention on the Rights of the Child, G.A. 
res. 44/25, annex, 44 U.N. GAOR Supp. (No. 49) at 167, U.N. Doc. A/44/49 (1989), entered into force September 2 1990, art. 24. 
122 International Covenant on Economic, Social and Cultural Rights (ICESCR), G.A. res. 2200A (XXI), 21 U.N.GAOR Supp. (No. 16) at 49, 
U.N. Doc. A/6316 (1966), 993 U.N.T.S. 3, entered into force January 3, 1976, art. 12. 
123 The Right to the Highest Attainable Standard of Health, Committee on Economic, Social and Cultural Rights, E/C.12/2000/4. 
(General Comments), 11 August 2000, I.12.(a). 
124 UN Committee on Economic, Social and Cultural Rights, “Substantive Issues Arising in the Implementation of the International 
Covenant on Economic, Social and Cultural Rights,” General Comment No. 14, The Right to the Highest Attainable Standard of Health, 
E/C.12/2000/4 (2000), http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/40d009901358b0e2c1256915005090be?Opendocument 
(accessed November 4, 2010), [hereinafter Substantive Issues Arising in the Implementation of the ICESCR, General Comment No. 14], 
paras. 30 and 33. 
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The CESCR has called for an integrated approach to the provision of “preventive, curative and 
rehabilitative health treatment,”125 which “should not disproportionately favour expensive 
curative health services which are often accessible only to a small, privileged fraction of the 
population.”126 The committee has specifically called for “attention and care for chronically and 
terminally ill persons, sparing them avoidable pain and enabling them to die with dignity.”127 
States must refrain from actions that interfere with access to palliative care and take reasonable 
steps to facilitate its development and its integration into the health care system as a whole.  
 
But the CESCR has also held that there are certain core obligations that are so fundamental 
that states must fulfill them. While resource constraints may justify only partial fulfillment of 
some aspects of the right to health, the committee has observed vis-à-vis the core 
obligations that “a State party cannot, under any circumstances whatsoever, justify its non-
compliance with the core obligations… which are non-derogable.”128 The committee has 
identified, among others, the following core obligations: 
 
• To ensure the right of access to health facilities, goods and services on a non-
discriminatory basis, especially for vulnerable or marginalized groups; 
• To provide essential drugs, as from time to time defined under the WHO Action 
Programme on Essential Drugs;  
• To ensure equitable distribution of all health facilities, goods and services;  
• To adopt and implement a national public health strategy and plan of action, on the 
basis of epidemiological evidence, addressing the health concerns of the whole 
population.129 
 
Relevant obligations of “comparable priority” include: ensuring child health care; taking 
measures to treat and control epidemic and endemic diseases; providing education and 
access to information for important health problems; and providing appropriate training for 
health personnel.130 The CESCR has also stressed the “obligation of all States parties to take 
                                                          
125 Ibid., para. 25. 
126 Ibid., para. 19. 
127 Ibid., para. 25. While the committee included this reference in a paragraph on the right to health for older persons, the 
wording clearly indicates that it applies to all chronically and terminally ill persons.  
128 The Right to the Highest Attainable Standard of Health, Committee on Economic, Social and Cultural Rights, 
E/C.12/2000/4. (General Comments), 11 August 2000, III.47. 
129 Ibid., para. 43.  
130 Ibid., para. 44. 
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steps, individually and through international assistance and cooperation … towards the full 
realization of the rights recognized in the Covenant, such as the right to health.”131 
 
Pain Treatment and the Right to the Highest Attainable Standard of Health 
As morphine and codeine are on the WHO Model List of Essential Medicines, countries must 
provide these medications as part of their core obligations under the right to health, 
regardless of whether they have been included on their domestic essential medicines 
lists.132 They must make sure that they are both available in adequate quantities and 
physically and financially accessible for those who need them. 
 
Because the manufacturing and distribution of controlled medicines including morphine and 
codeine are entirely within government control, states need to put in place an effective 
procurement and distribution system and create a legal and regulatory framework that 
enables health care providers in both the public and private sector to obtain, prescribe and 
dispense these medications. Any regulations that arbitrarily impede the procurement and 
dispensing of these medications will violate the right to health. 
 
States need to adopt and implement a strategy and plan of action for the roll-out of pain 
treatment and palliative care services. Such strategy and plan of action should identify 
obstacles to improved services as well as steps to eliminate them. States should regularly 
measure progress made in ensuring availability and accessibility of pain relief medications. 
 
The requirement of physical accessibility means that pain medications must be “within safe 
physical reach for all sections of the population, especially vulnerable or marginalized 
groups, such as … persons with HIV/AIDS.”133 This means that states should ensure that a 
sufficient number of health care providers or pharmacies stock and dispense morphine and 
codeine and that an adequate number of healthcare workers are trained and authorized to 
prescribe these medications. 
 
                                                          
131 Ibid., para. 38. 
132 World Health Organization, “Model List of Essential Medicines - 16th List,” March 2009, 
http://www.who.int/selection_medicines/committees/expert/17/sixteenth_adult_list_en.pdf (accessed 6 August 2010), 
includes the following opioid analgesics: Codeine Tablet: 30 mg (phosphate); Morphine Injection: 10 mg (morphine 
hydrochloride or morphine sulfate) in 1‐ml ampoule; Oral liquid: 10 mg (morphine hydrochloride or morphine sulfate)/5 ml., 
Tablet: 10 mg (morphine sulfate); Tablet (prolonged release): 10 mg; 30 mg; 60 mg (morphine sulfate). 
133 Substantive Issues Arising in the Implementation of the ICESCR, General Comment No. 14, para. 12. 
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Financial accessibility means that, while the right to health does not require states to offer 
medications free of charge, they must be “affordable for all.”134 In the words of the CESCR: 
 
Payment for health-care services…has to be based on the principle of equity, 
ensuing that these services, whether privately or publicly provided, are 
affordable to all, including socially disadvantaged groups. Equity demands 
that poorer households should not be disproportionately burdened with 
health expenses as compared to richer households.135 
 
Countries also have an obligation to progressively implement palliative care services, 
which, according to WHO, must have “priority status within public health and disease 
control programmes.”136 Countries need to ensure an adequate policy and regulatory 
framework, develop a plan for implementation of these services, and take all steps that 
are reasonable within available resources to execute the plan. Failure to attach adequate 
priority to developing palliative care services within health care services will likely violate 
the right to health. 
 
Pain Treatment and the Right to Be Free from Cruel, Inhuman, and  
Degrading Treatment 
The right to be free from torture, cruel, inhuman, and degrading treatment or punishment is a 
fundamental human right that is recognized in numerous international human rights 
instruments.137 Apart from prohibiting the use of torture, cruel, inhuman, and degrading 
                                                          
134 Ibid. 
135 Ibid. 
136 World Health Organization, “National Cancer Control Programs: Policies and Managerial Guidelines,” 2002, 
http://www.who.int/cancer/media/en/408.pdf (accessed August 6, 2010) pp. 86. 
137 International Covenant on Civil and Political Rights (ICCPR), adopted December 16, 1966, G.A. Res. 2200A (XXI), 21 U.N. 
GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, entered into force March 23, 1976, art. 7 provides, “No 
one shall be subjected to torture or to cruel, inhuman or degrading treatment or punishment”; Universal Declaration of Human 
Rights (UDHR), adopted December 10, 1948, G.A. Res. 217A(III), U.N. Doc. A/810 at 71 (1948); Convention against Torture and 
Other Cruel, Inhuman or Degrading Treatment or Punishment (Convention against Torture), adopted December 10, 1984, G.A. 
res. 39/46, annex, 39 U.N. GAOR Supp. (No. 51) at 197, U.N. Doc. A/39/51 (1984), entered into force June 26, 1987, article 16 
provides that “Each State Party shall undertake to prevent in any territory under its jurisdiction other acts of cruel, inhuman or 
degrading treatment or punishment which do not amount to torture as defined in article I, when such acts are committed by or 
at the instigation of or with the consent or acquiescence of a public official or other person acting in an official capacity”; 
Inter-American Convention to Prevent and Punish Torture, O.A.S. Treaty Series No. 67, entered into force February 28, 1987; 
European Convention for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment (ECPT), signed 
November 26, 1987, E.T.S. 126, entered into force February 1, 1989; African [Banjul] Charter on Human and Peoples' Rights, 
adopted June 27, 1981, OAU Doc. CAB/LEG/67/3 rev. 5, 21 I.L.M. 58 (1982), entered into force October 21, 1986. 
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treatment or punishment, the right also creates a positive obligation for states to protect 
persons in their jurisdiction from such treatment.138 
 
As part of this positive obligation, states have to take steps to protect people from unnecessary 
pain related to a health condition. As the UN Special Rapporteur on torture, cruel, inhuman and 
degrading treatment and punishment wrote in a joint letter with the UN Special Rapporteur on 
the right to health to the commission on narcotic drugs in December 2008: 
 
Governments also have an obligation to take measures to protect people 
under their jurisdiction from inhuman and degrading treatment. Failure of 
governments to take reasonable measures to ensure accessibility of pain 
treatment, which leaves millions of people to suffer needlessly from severe 
and often prolonged pain, raises questions whether they have adequately 
discharged this obligation.139 
 
In a report to the Human Rights Council, Manfred Nowak, then-special rapporteur on 
torture, cruel, inhuman and degrading treatment and punishment, specified that “the de 
facto denial of access to pain relief, if it causes severe pain and suffering, constitutes 
cruel, inhuman or degrading treatment or punishment” and that “all measures should be 
taken to … overcome current regulatory, educational and attitudinal obstacles to ensure 
full access to palliative care.”140 
 
Not every case where a person suffers from severe pain but has no access to appropriate 
treatment will constitute cruel, inhuman, or degrading treatment or punishment. Human 
Rights Watch believes that this will only be the case when the following conditions are met: 
 
• The suffering is severe and meets the minimum threshold required under the 
prohibition of torture and cruel, inhuman, or degrading treatment; 
• The state is, or should be, aware of the level and extent of the suffering; 
• Treatment is available to remove or lessen the suffering but no appropriate treatment 
is offered; and 
                                                          
138 See for example the judgment of the European Court of Rights in Z v United Kingdom (2001) 34 EHRR 97. 
139 Joint letter by the UN special rapporteur on the prevention of torture and cruel, inhuman or degrading treatment or punishment, 
Manfred Nowak, and the UN special rapporteur on the right of everyone to the enjoyment of the highest attainable standard of 
physical and mental health, Anand Grover, to the Commission on Narcotic Drugs, December 2008. A copy of the letter is available at 
http://www.ihra.net/Assets/1384/1/SpecialRapporteursLettertoCND012009.pdf (accessed April 27, 2010). 
140 Human Rights Council, Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or 
punishment, Manfred Nowak, U.N. Doc. A/HRC/10/44, January 14, 2009, paras. 72 and 74(e).  
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• The state has no reasonable justification for the lack of availability and accessibility 
of pain treatment. 
 
In such cases, states will be liable for failing to protect a person from cruel, inhuman, or 
degrading treatment. 
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IX. Recommendations 
 
The palliative care and pain treatment gap is an international human rights crisis that needs 
to be addressed urgently both at the international and national level. Therefore, Human 
Rights Watch makes the following recommendations:  
  
To Governments around the World  
General  
• Establish, where this has not yet been done, a working group on palliative care and 
pain management. This working group should include all relevant actors, including 
health officials, drug regulators, health care providers, nongovernmental palliative 
care providers, and academics, and develop a concrete plan of action for the 
progressive implementation of pain treatment and palliative care services.  
• Assess both the availability of and the need for pain management and palliative care 
services.  
• Develop a comprehensive plan of action that addresses the various barriers that 
impede availability of pain management and palliative care, including government 
policy, education, and availability of medications.  
• Invite the WHO Access to Controlled Medications Programme to assist in 
implementing the above recommendations.  
• National human rights commissions or ombudsman offices should, where possible, 
investigate obstacles to availability of pain management and palliative care services, 
and request that their governments take urgent measures to address them.  
  
Ensuring an Effective Supply System  
• Submit, in a timely fashion, realistic estimates for the need of controlled 
medications to the INCB.  
• Ensure an effective distribution system for controlled medications. While 
procurement, transportation, and stocking regulations should be able to prevent 
potential abuse, they should not arbitrarily complicate these processes.  
• Countries must ensure that in each region at least a minimum number of pharmacies 
and hospitals stock morphine.  
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Developing and Enacting Pain Management and Palliative Care Policies  
• Recognize a human rights obligation to provide effective/adequate palliative care 
programs.  
• Develop official policies on pain management and palliative care, including as part 
of cancer and HIV/AIDS control programs. 
• Develop practical guidelines on pain management and palliative care for healthcare 
workers. 
• Include oral morphine and other essential pain treatment medications in national 
lists of essential medicines. 
• Ensure that drug control laws and regulations recognize the indispensible nature of 
opioid and other controlled medicines for the relief of pain and suffering, as well as 
the obligation to ensure their adequate availability.  
  
Ensuring Instruction for Healthcare Workers  
• Ensure adequate instruction for healthcare workers, including doctors, nurses, and 
pharmacists, at both undergraduate and postgraduate level.  
• Instruction should also be offered to those already practicing as part of continuing 
medical education.  
  
Reforming Drug Regulations  
• Review drug control regulations to assess whether they unnecessarily impede 
accessibility of pain medications. Health care providers should participate in 
conducting this review.  
• If regulations are found to impede access, they should be amended.  
• Recommendations of WHO and health care providers should be a starting point of 
revised drug control regulations.  
• Requiring special licenses for health care institutions or providers to handle 
morphine should be avoided as much as possible. In other cases, transparent and 
simple procedures should be established for obtaining such special licenses.  
• Special prescription procedures for controlled medications should be avoided as much 
as possible. Where they are nonetheless in place, they should be minimally burdensome.  
• Limitations on the amount of morphine that can be prescribed per day should be 
abolished.  
• Unnecessary limitations on the amount of morphine that can be prescribed or 
dispensed at once should be abolished. 
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Ensuring Affordability of Medications  
• Countries should seek to ensure the affordability of morphine and other opioid 
analgesics.  
  
To Global Drug Policy Makers  
• Restore the balance between ensuring availability of controlled medicines and 
preventing abuse, as provided for by the UN drug control conventions, in global drug 
policy debates. Access to controlled medicines should be a central and recurring agenda 
item at the Commission on Narcotic Drugs and other meetings on global drug policy.  
• The Commission on Narcotic Drugs and the INCB should regularly review progress 
made by countries toward adequate availability of pain treatment medicines, 
carefully analyzing steps taken to advance this important issue.  
• INCB should significantly increase its efforts to encourage and assist states in 
improving availability of opioid analgesics.  
• UNODC should amend the model laws and regulations it has developed to include 
recognition of the indispensible nature of narcotic drugs and psychotropic 
substances for medical and scientific purposes and the obligation for states to 
ensure their availability.  
• UNODC and the INCB should develop processes to ensure that human rights, 
including the right to the highest attainable standard of health, are systematically 
considered in their work.  
 
To the WHA, WHO, UNAIDS, and the Donor Community 
• The World Health Assembly (WHA) should adopt a resolution calling upon its 
member states to promote universal access to pain management and palliative care, 
by taking steps to ensure that their health policies and services address the needs of 
all patients with life-limiting illness, including by ensuring the availability of pain 
medicines and training in pain treatment and palliative care for healthcare workers.  
• WHO should continue to treat access to controlled medicines with urgency through 
its Access to Controlled Medications Programme.  
• Donor countries and agencies, including the Global Fund to fight AIDS, Malaria, and 
Tuberculosis and the U.S. President’s Emergency Plan for AIDS Relief, should actively 
encourage countries to undertake comprehensive steps to improve access to pain 
relief medications and support those that do, including through support for the WHO 
Access to Controlled Medications Programme.  
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• UNAIDS should work with governments to identify and remove obstacles to 
availability and accessibility of pain management and palliative care services.  
 
To the Global Human Rights Community  
• UN and regional human rights bodies should routinely remind countries of their 
obligation under human rights law to ensure adequate availability of pain medicines.  
• UN human rights procedures that monitor the right to the highest attainable 
standard of health and the prohibition on cruel, inhuman and degrading treatment 
should regularly consider the availability of pain medicines and governments’ efforts 
to make them available.  
• Human rights groups should include access to pain treatment and palliative care into 
their work, including by submitting shadow reports to UN treaty bodies, providing 
information to the UN Special Rapporteurs on the highest attainable level of health 
and on torture, cruel, inhuman and degrading treatment and punishment to the 
Human Rights Council.  
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X. Methodology 
 
This report presents information on barriers to accessing pain treatment in 40 countries.  
 
Countries were selected in two steps to ensure a broad and diverse sample. First, the five 
most populous countries in each of the six WHO regions were chosen. Second, specific 
countries were selected where additional diversity of experience or in-depth understanding 
of experience was desired.  
 
In Europe, 10 countries were selected in order to include a range of countries from both 
Western Europe and formerly Communist countries of Eastern and Central Europe. Countries 
in different regions (including Cameroon, Uganda, El Salvador, Ecuador, Guatemala, Jordan, 
Georgia, and Cambodia) where Human Rights Watch had on-going work were also included.  
 
From this overall list of countries, four countries were excluded because collecting 
information was impractical or constituted an unacceptable level of risk for the healthcare 
workers (the Democratic Republic of Congo, Uzbekistan, Burma, and Sudan). In their place, 
the next-most-populous country in the relevant WHO region was chosen. Among selected 
countries, one (Italy), was excluded after repeated efforts to contact appropriate survey 
respondents yielded no responses.  
 
The primary means of collecting this data was surveying healthcare workers by telephone 
interview. The survey questions (see Annex 2) ask about common barriers to access to pain 
treatment identified in Human Rights Watch’s March 2009 report: “Please, do not make us 
suffer any more…”: Access to Pain Treatment as a Human Right. The telephone interviews 
took place between July 2009 and October 2010.  
 
The healthcare workers interviewed for this research were identified through professional 
associations and nongovernmental organizations that work on access to pain treatment and 
palliative care. Two survey respondents were interviewed in each country except Guatemala, 
China, and Cambodia, where there were three survey respondents. Most survey respondents 
(77 of 82) were medical doctors, many of whom also held academic appointments. Three 
survey respondents were nurses, one was the head of a national hospice and palliative care 
association with experience as a hospice administrator, and one was a technical advisor for 
a nongovernmental organization working to integrate palliative care into the country’s health 
system. Many of the healthcare workers were palliative care specialists; others were 
specialists in pain management, anesthesiology, or oncology.  
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Healthcare workers were initially contacted by email, with a description of the project and 
the survey questions. Healthcare workers who agreed to participate were then interviewed 
by telephone to collect their survey responses. At the preference of the respondent, 
interviews were conducted in English, Spanish, French, Russian, or Mandarin. In addition, 
internet research was used to gather secondary materials relevant to the survey questions, 
such as national palliative care policies, cancer and HIV/AIDS control policies, essential 
medicines lists, and drug control laws and regulations.  
 
The healthcare workers’ survey responses and the results of the secondary research were 
compared and the healthcare workers were then contacted by email seeking clarification of 
discrepancies between the survey answers they each provided or between their answers and 
any relevant documents collected. Survey respondents from 35 countries responded with 
clarifying information.  
 
Once clarifying information was received, letters presenting the survey results were sent to 
the Ministry of Health and the Competent National Authority—the body responsible for 
implementing the 1961 Single Convention on Narcotic Drugs—in each country. The letters 
explained the research and invited clarification of the initial research findings or additional 
relevant information. The letters were sent by post and, where possible, fax or email. Replies 
were received from Poland, Jordan, Georgia, Uganda, and El Salvador.  
 
The initial survey results were also published on a password protected website. Through the 
email newsletters of the Worldwide Palliative Care Alliance and the International Association 
for Hospice and Palliative Care, members of these organizations were invited to comment on 
the initial findings with clarifications or additional relevant information.  
 
The maps and tables of opioid consumption in this report were prepared using publically 
available data to compare the availability of medicines to treat moderate to severe pain in 
countries around the globe.141 Data on each country’s consumption of the principal 
medicines used to treat moderate to severe pain is published each year by the International 
Narcotics Control Board.142 Using expert estimates of the prevalence and severity of pain in 
                                                          
141 This method was adapted from the methodology presented in Seya et al., “A First Comparison Between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional, and Global Levels,” Journal of Pain & Palliative Care 
Pharmacotherapy, vol. 25, (2001), p. 6.  
142 International Narcotics Control Board, “Narcotic Drugs: Estimated World Requirements for 
2010: Statistics for 2008,” 2010, http://www.incb.org/incb/en/narcotic_drugs_reports.html (accessed 27 October 2010) pp. 208 – 258.  
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terminal cancer and HIV/AIDS patients,143 and WHO data on cancer and HIV/AIDS 
mortality,144 a calculation of each country’s ability to provide pain treatment for its terminal 
cancer and HIV/ AIDS patients was made, as an indicator of the availability of treatment for 
all patients with moderate to severe pain in the country. A table of relevant data and 
calculations can be found in appendix 3.  
 
Survey responses are presented in five regional chapters: Africa, Americas, Europe, the 
Middle East, and North Africa (corresponding to WHO’s Eastern Mediterranean Region) and 
Asia (corresponding to WHO’s South East Asia and Western Pacific Regions).  
                                                          
143 Kathleen M. Foley et al., “Pain Control for People with Cancer and AIDS,” in Dean T. Jamison et al., eds., Disease Control 
Priorities in Developing Countries, 2nd ed. (New York: Oxford University Press, 2006), p. 982.  
144 World Health Organisation, “Global Health Observatory,” 2009, http://apps.who.int/ghodata/ (accessed 28 October 2010). 
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Appendix 1 – List of Survey Participants 
 
Argentina Dr. Roberto Wenk 
Dr. Vilma Tripodoro  
Bangladesh Professor Ahmed Nezamuddin 
Dr. Rumana Dowla 
Brazil Dr. Roberto Bettega  
Dr. Ana Claudia Arantes 
Cambodia Dr. Celine Lebost  
Beris Bird 
Dr. Pierre Regis 
Cameroon Dr. Jonah Wefuan  
Ndikintum George Mbeng 
China Dr. Jinxiang Li  
Dr. Limin Lao 
Anonymous 
Colombia Dr. Marta Leon  
Dr. John Jairo Vargas  
Ecuador Dr. Nicky Bailhache 
Dr. Maria Cervantes 
Egypt Anonymous 
Anonymous  
El Salvador Dr. Roland Arturo Larin Lovo 
Dr. Carlos Rivas 
Ethiopia  Anonymous 
Dr. Solomon Bogale 
France Dr. Marilene Filbet 
Dr. Jean Bruxelle 
Georgia Anonymous  
Dr. Dimitri Kordzaia 
Germany Dr. Lucas Radbruch  
Dr. Rolf-Detlef Treede 
Guatemala Dr. Eva Rossina Duarte  
Dr. Silvia Rivas  
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Dr. Marisol Bustamante 
India Dr. M R Rajagopal 
Dr. Anil Paleri  
Indonesia Anonymous 
Anonymous 
Iran Anonymous 
Anonymous 
Japan Dr. Toshihiko Nakatani 
Dr. Etsuko Aruga 
Jordan Dr. Mohammad Bushnaq 
Dr. Maha Arnaout 
Kazakhstan Anonymous 
Anonymous  
Kenya Dr. Zipporah Ali  
Dr. John Weru 
South Korea Dr. Young Seon Hong  
Youn Seon Choi  
Mexico Dr. Paola Andrea Zuluaga 
Dr. Antonia Tamayo-Valenzuela  
Morocco Dr. Mat Nejmi 
Professor Mhamed Harif  
Nepal Dr. Bishnu Dutta Paudel 
Anonymous 
Nigeria Dr. Folaju Oyebola 
Dr. Simbo Amanor-Boadu 
Pakistan Dr. Haroon Hafeez 
Dr. Mohammad Saleem 
Philippines Dr. Francis Javier  
Dr. Henry Lu  
Poland  Dr. Tomasz Dzierżanowski 
Dr. Wojciech Leppert 
Romania Dr. Daniela Mosoiu 
Dr. Constantin Bogdan  
Russia Anonymous  
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Anonymous 
South Africa Dr. Liz Gwyther 
Dr. Rene Albertyn 
Tanzania Dr. Mark Jacobson 
Anonymous 
Thailand  Dr. Sakon Singha  
Dr. Pongparadee Chaudakshetrin  
Turkey Dr. Ozgur Ozyilkan 
Professor Serdar Erdine 
Uganda  Dr. Henry Ddungu 
Dr. Anne Merriman 
Ukraine Dr. Viktoria Tymoshevska  
Dr. Ljudmila Andriishin 
United Kingdom Dr. Bill Noble 
Dr. Ros Taylor 
United States Dr. Aaron Gilson 
Dr. Don Schumacher  
Vietnam  Kimberly Green  
Dr. Eric Krakauer 
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Appendix 2 – Survey Questions 
 
Global State of Opioid Availability for Pain Treatment 
Survey of national experts 
 
Thank you for agreeing to participate in our survey regarding access to pain treatment.  
 
• During your telephone interview, you will be asked the following questions. You do 
not need to write down your responses.  
 
• If you do not know the answer to any of our questions, we would greatly appreciate 
your efforts to find the relevant information, for example by asking other doctors or a 
government agency.  
 
• We would also very much appreciate copies of any relevant laws, regulations or 
policies that you have access to.  
 
Policy  
 
1. Does this country have a national palliative care policy? 
 Yes   No  Don’t know 
 
2. Are there references to pain management or palliative care in the national cancer control 
policy? 
 Yes   No  Don’t know  No national cancer control policy 
 
3. Are there references to pain management or palliative care in the national AIDS policy? 
 Yes   No  Don’t know  No national AIDS policy 
 
4. Is oral morphine a registered medicine? 
 Yes   No  Don’t know  
 
5. Is injectable morphine on the national Essential Medicines List? 
 Yes   No  Don’t know  No Essential Medicines List 
 
6. Is oral morphine on the national Essential Medicines List? 
 Yes   No  Don’t know  No Essential Medicines List 
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Prescription procedures 
 
7. Can morphine be prescribed for home use? 
 Yes   No  Don’t know 
 
8. Is the prescription form for morphine different to the regular prescription form? 
 Yes   No  Don’t know 
9. Is the signature of more than one doctor required on a prescription for morphine? 
 Yes   No  Don’t know 
 
10. Is the right to prescribe morphine limited to doctors in certain specialties (i.e. 
oncologists)? 
 Yes, the specialists that can prescribe are: _________________ ___________________ 
  No  Don’t know 
 
11. Do doctors need a special license to prescribe morphine (in addition to their license to 
practice medicine)? 
 Yes   No  Don’t know 
 
11a. If a special license is required, how difficult is it to obtain? 
 Not difficult   somewhat difficult very difficult 
 
12. Can any health professionals other than doctors obtain a license to prescribe morphine? 
(For example, specially trained nurses) 
 Yes, the health professionals that can obtain a license to prescribe are:____________  
 No  Don’t know 
 
13. What is the maximum number of days that morphine can be prescribed for an out-
patient, using one prescription? 
Number of days:__ __  Don’t know  morphine cannot be prescribed for out-patients  
 
14. Is there limit on the dose of morphine that may be prescribed? 
 Yes: limit is:________  No   Don’t know 
 
Medical education 
Definition: for the purpose of these questions, pain management means using opioids and 
other drugs to manage acute and chronic pain. Anesthesia is not pain management. Pain 
management may be taught as a component of palliative care, but need not be.  
 
15. Is instruction in pain management: 
Available in undergraduate medical programs:  none  some  most  all  don’t know 
Compulsory in undergraduate programs:   none  some  most  all  don’t know  
Available in post-graduate medical education:   Yes    No   Don’t know 
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Availability 
16. Is injectable morphine available in hospitals:   
 none  some  most  all  don’t know 
 
17. Is oral morphine available in: 
Tertiary hospitals  none  some  most  all   don’t know 
Other hospitals  none  some  most  all   don’t know 
Pharmacies  none  some  most  all   don’t know 
Health centres  none  some  most  all   don’t know 
Hospices    none  some  most  all   don’t know  no hospices 
AIDS clinics  none  some  most  all   don’t know  no AIDS clinics 
 
18. Question for general discussion: Is it harder to access morphine outside of major cities?  
 
19. Cost 
• Please indicate the price that a patient pays for each morphine formulation at your 
own health service.  
• For hospital in-patients and pharmacies, please assume that the patient obtains the 
morphine from the cheapest source, but not where its cost is subsidized by private 
donors.  
• Please indicate if you do not know the price of a formulation or if it is unavailable at 
a particular location.  
Formulation Your health service Hospital in-patients Pharmacies  
Injectable  10mg/1ml ampoule    
Oral liquid 10mg/5ml    
Immediate release tablet 10mg     
Sustained release tablet 10mg    
Sustained release tablet 30mg    
Sustained release tablet 60mg    
 
Other questions for general discussion: 
20. Are doctors hesitant to prescribe opioids because of fear of legal sanction for 
mishandling them, such as prosecution or license revocation?  
 
21. The International Narcotics Control Board recommends that governments consult palliative 
care providers when making their estimates of the country’s need for opioids for medical 
purposes. Are palliative care providers consulted regarding the national estimate? 
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Appendix 3 – Table of Calculations Used to Produce Maps  
Opioid Consumption and Percentage of Terminal Cancer  
and AIDS Patients Each Country Can Treat 
 
Table 1: Annual Cancer and AIDS Deaths, Average Morphine Consumption 2006-2008, and 
Percentage of Terminal AIDS and Cancer Patients that Could be Treated with Morphine 
Consumed 
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Afghanistan 27208 0 82.5 1 22442 109.07 N/A N/A N/A N/A N/A  
Albania 3143 0 146.2 9 4595 22.36 1.0 4.0 1.0 2.0 9% 329 
Algeria 34373 2 56.7 532 19474 96.26 2.0 2.0 4.0 2.7 3% 439 
Andorra 84 4 227.5 3 191 0.94 0.25 0.25  0.3 27% 41 
Angola 18021 66 75.7 11941 13650 102.61 0.25   0.3 0% 41 
Antigua and Barbuda 87 16 155.8 14 136 0.70     0% 0 
Argentina 39883 4 157.8 1751 62923 311.12 25.0 449.0 356.0 276.7 89% 45542 
Armenia 3077 2 210.4 74 6475 31.69 2.0 4.0 2.0 2.7 8% 439 
Australia 21074 1 192.5 112 40568 197.50 1079.0 1093.0 1012.0 1061.3 537% 174705 
Austria 8337 1 235.6 56 19644 95.64 1274.0 1274.0 1385.0 1311.0 1371% 215802 
Azerbaijan 8731 0 91.4 7 7980 38.80 1.0 1.0 1.0 1.0 3% 165 
Bahamas 338 57 93.6 192 317 2.12 1.0 1.0 0.25 0.8 35% 123 
Bahrain 776 3 50.5 22 392 1.97 1.0 1.0 1.0 1.0 51% 165 
Bangladesh 160000 0 56.4 118 90242 438.93 3.0 2.0 5.0 3.3 1% 549 
Barbados 255 29 166.9 74 425 2.29 2.0   2.0 87% 329 
Belarus 9679 8 199.2 800 19276 96.11 6.0 5.0 5.0 5.3 6% 878 
Belgium 10590 1 278.3 69 29471 143.44 136.0 131.0 135.0 134.0 93% 22058 
Belize 301 24 68.5 72 206 1.22 N/A N/A N/A N/A N/A N/A 
Benin 8662 43 58.8 3752 5093 36.15 0.25 0.25 0.25 0.3 1% 41 
Bhutan 687 0 59.0 0 405 1.97 0.0 0.25  0.1 6% 21 
Bolivia 9694 4 139.3 416 13505 66.90  0.0 0.0 0.0 0% 0 
Bosnia and Herzegovina 3773 0 164.0 11 6189 30.11  0.25 4.0 2.1 7% 350 
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Botswana 1921 825 48.4 15847 930 52.66 0.25 3.0 0.25 1.2 2% 192 
Brazil 191972 9 104.6 17607 200753 1029.14 657.0 312.0 430.0 466.3 45% 76763 
Brunei Darussalam 392 0 53.2 0 209 1.01 0.25 0.25 0.25 0.3 25% 41 
Bulgaria 7593 0 216.0 22 16399 79.77 47.0 66.0 53.0 55.3 69% 9108 
Burkina Faso 15234 66 70.3 9998 10707 82.40 0.25 0.25  0.3 0% 41 
Burundi 8074 167 63.0 13459 5089 65.61 0.25 0.25 0.25 0.3 0% 41 
Cambodia 14562 70 78.8 10193 11476 86.73 0.0 0.25 0.25 0.2 0% 27 
Cameroon 19088 228 71.1 43447 13572 197.93     0% 0 
Canada 33259 1 209.2 462 69587 339.59 2003.0 2299.0 2434.0 2245.3 661% 369602 
Cape Verde 499 1 51.0 4 254 1.25 0.25 0.25  0.3 20% 41 
Central African Republic 4339 252 77.6 10930 3368 49.57 0.25   0.3 1% 41 
Chad 10914 113 69.0 12337 7533 74.08   0.25 0.3 0% 41 
Chile 16804 3 131.7 443 22131 108.90 59.0 55.0 62.0 58.7 54% 9657 
China 1344920 2 136.0 21017 1828511 8950.40 548.0 640.0 906.0 698.0 8% 114897 
Colombia 45012 13 81.5 5692 36704 195.67 49.0 75.0 55.0 59.7 30% 9822 
Comoros 661 1 47.8 8 316 1.56     0% 0 
Congo 3615 220 53.9 7961 1948 33.65 0.25   0.3 1% 41 
Cook Islands 20 0 43.9 0 9 0.04 0.0 0.3  0.1 293% 21 
Costa Rica 4519 3 91.8 136 4150 20.58 12.0 0.0 13.0 8.3 40% 1372 
Cote d'Ivoire 20591 260 78.4 53495 16135 240.91 0.3 0.25 0.25 0.3 0% 41 
Croatia 4423 0 284.5 3 12582 61.16 8.0 8.0 8.0 8.0 13% 1317 
Cuba 11205 1 171.1 111 19171 93.51 15.0 14.0 11.0 13.3 14% 2195 
Cyprus 862 0 113.0 0 974 4.73 2.0 2.0 2.0 2.0 42% 329 
Czech Republic 10319 0 287.3 3 29642 144.07 58.0 54.0 53.0 55.0 38% 9053 
Democratic People's 
Republic of Korea 
23819 0 94.8 37 22588 109.89 19.0 18.0 19.0 18.7 17% 3073 
Democratic Republic of 
the Congo 
64257 127 61.6 81738 39574 440.61 0.25 0.25 11.0 3.8 1% 631 
Denmark 5458 1 292.8 31 15981 77.76 301.0 293.0 264.0 286.0 368% 47078 
Djibouti 849 112 52.4 947 445 5.04     0% 0 
Dominica 67 20 159.6 14 107 0.56 0.25 0.25 0.25 0.3 45% 41 
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Dominican Republic 9953 46 109.8 4598 10932 67.09 5.0 3.0 4.0 4.0 6% 658 
Ecuador 13481 9 87.0 1251 11727 60.79 3.0 2.0 5.0 3.3 5% 549 
Egypt 81527 0 55.6 391 45329 221.49 1.0 9.0 12.0 7.3 3% 1207 
El Salvador 6134 23 72.2 1389 4430 25.75 0.25 0.25 2.0 0.8 3% 137 
Equatorial Guinea 659 148 91.4 974 602 5.89 N/A N/A N/A N/A N/A N/A 
Eritrea 4927 46 40.9 2265 2014 16.67 0.25 0.25 0.25 0.3 2% 41 
Estonia 1341 2 269.3 22 3612 17.62 6.0 6.0 5.0 5.7 32% 933 
Ethiopia 80713 122 57.1 98157 46107 522.23 0.25 0.25 4.0 1.5 0% 247 
Fiji 844 2 52.6 13 444 2.20 N/A N/A N/A N/A N/A N/A 
Finland 5304 0 201.6 8 10694 52.00 22.0 21.0 19.0 20.7 40% 3402 
France 62036 2 272.5 1153 169042 825.05 2651.0 2302.0 2354.0 2435.7 295% 400933 
Gabon 1448 209 77.4 3021 1120 14.62     0% 0 
Gambia 1660 30 73.2 492 1215 7.40 0.0   0.0 0% 0 
Georgia 4307 0 90.3 4 3890 18.92 8.0 6.0 6.0 6.7 35% 1097 
Germany 82264 1 261.1 544 214767 1045.42 1278.0 1900.0 1851.0 1676.3 160% 275940 
Ghana 23351 97 64.8 22642 15125 142.28 2.0 1.0 0.25 1.1 1% 178 
Greece 11137 0 247.1 17 27518 133.79 5.0 6.0 5.0 5.3 4% 878 
Grenada 104 19 148.0 20 154 0.81 0.25 0.25  0.3 31% 41 
Guatemala 13686 15 65.0 2054 8891 49.45 5.0 1.0 5.0 3.7 7% 604 
Guinea 9833 40 67.1 3951 6595 44.06     0% 0 
Guinea-Bissau 1575 60 69.2 937 1090 8.14     0% 0 
Guyana 763 82 84.8 628 647 5.05 0.25 0.25 0.0 0.2 3% 27 
Haiti 9876 92 55.4 9098 5471 54.22 0.25 0.25 0.25 0.3 0% 41 
Honduras 7319 34 77.3 2467 5656 34.98 0.0 0.0  0.0 0% 0 
Hungary 10012 0 328.5 12 32892 159.89 22.0 17.0 13.0 17.3 11% 2853 
Iceland 315 0 179.1 0 564 2.74 8.0 12.0 10.0 10.0 365% 1646 
India 1181412 11 65.3 133404 771728 4155.81 224.0 693.0 355.0 424.0 10% 69794 
Indonesia 227345 0 89.2 298 202830 986.66 6.0 10.0 10.0 8.7 1% 1427 
Iran (Islamic Republic of) 73312 2 63.4 1803 46467 231.30 0.0 0.0 0.0 0.0 0% 0 
Iraq 30096 0 84.4 6 25389 123.41   1.0 1.0 1% 165 
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Ireland 4437 1 204.4 29 9071 44.18 47.0 39.0 39.0 41.7 94% 6859 
Israel 7051 0 142.1 30 10018 48.78 36.0 33.0 38.0 35.7 73% 5871 
Italy 59604 1 272.5 883 162425 792.07 172.0 105.0 855.0 377.3 48% 62112 
Jamaica 2708 44 124.5 1204 3373 20.05 3.0 2.0 4.0 3.0 15% 494 
Japan 127293 0 252.9 51 321958 1564.87 436.0 382.0 341.0 386.3 25% 63594 
Jordan 6136 0 60.3 29 3702 18.08 6.0 11.0 8.0 8.3 46% 1372 
Kazakhstan 15521 2 153.7 268 23857 116.76  0.25 4.0 2.1 2% 350 
Kenya 38765 375 48.4 145274 18774 532.51 5.0 22.0 2.0 9.7 2% 1591 
Kiribati 97 0 34.5 0 33 0.16     0% 0 
Kuwait 2919 0 21.5 6 629 3.08 1.0 1.0 1.0 1.0 33% 165 
Kyrgyzstan 5414 0 77.2 22 4182 20.39 0.25 1.0 0.25 0.5 2% 82 
Lao People's Democratic 
Republic 
6205 0 67.9 27 4211 20.55 0.25 0.25 0.25 0.3 1% 41 
Latvia 2259 1 259.3 16 5857 28.52 4.0 5.0 5.0 4.7 16% 768 
Lebanon 4194 4 77.3 176 3242 16.29 4.0 4.0 4.0 4.0 25% 658 
Lesotho 2049 801 56.8 16422 1164 55.54  0.25 0.25 0.3 0% 41 
Liberia 3793 57 56.7 2156 2150 17.00 N/A N/A N/A N/A N/A N/A 
Libyan Arab Jamahiriya 6294 5 45.9 338 2888 15.06 0.25 0.25  0.3 2% 41 
Lithuania 3321 0 234.5 7 7789 37.87 9.0 9.0 10.0 9.3 25% 1536 
Luxembourg 481 1 215.1 4 1035 5.04 4.0 4.0 4.0 4.0 79% 658 
Madagascar 19111 3 61.5 489 11744 58.56 0.3 0.3 0.3 0.3 0% 41 
Malawi 14846 506 55.9 75165 8302 268.66 0.3 0.3 0.3 0.3 0% 41 
Malaysia 27014 8 83.6 2069 22586 116.05 26.0 24.0 29.0 26.3 23% 4335 
Maldives 305 19 148.9 58 454 2.38  0.3  0.3 10% 41 
Mali 12706 44 78.6 5584 9984 65.48 0.3 0.3 0.3 0.3 0% 41 
Malta 407 0 183.5 2 747 3.63 2.0 5.0 3.0 3.3 92% 549 
Marshall Islands 61 1 85.3 0 52 0.25 0.3 0.3  0.3 98% 41 
Mauritania 3215 15 68.8 488 2211 12.23 0.3 0.3  0.3 2% 41 
Mauritius 1280 2 77.9 22 997 4.91 0.3 1.0  0.6 13% 103 
Mexico 108555 5 69.2 5008 75168 380.53 29.0 36.0 37.0 34.0 9% 5597 
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Micronesia (Federated 
States of) 
110 0 48.0 0 53 0.26 0.3   0.3 97% 41 
Monaco 33 3 210.6 1 70 0.34 N/A N/A N/A N/A N/A N/A 
Mongolia 2641 0 158.3 1 4182 20.33 2.0 0.0 6.0 2.7 13% 439 
Morocco 31606 2 44.6 700 14105 70.68 5.0 9.0 7.0 7.0 10% 1152 
Mozambique 22383 349 59.7 78158 13369 302.38 1.0 0.3 6.0 2.4 1% 398 
Myanmar 49563 45 83.4 22308 41338 268.66 2.0 0.3 0.3 0.8 0% 137 
Namibia 2130 479 40.7 10213 867 35.24 2.0 5.0 1.0 2.7 8% 439 
Nauru 10 5 83.4 1 8 0.04 0.3   0.3 594% 41 
Nepal 28810 1 63.0 255 18144 88.95 1.0 5.0 6.0 4.0 4% 658 
Netherlands 16528 1 250.3 95 41368 201.34 151.0 368.0 101.0 206.7 103% 34019 
New Zealand 4230 0 193.7 10 8195 39.86 204.0 83.0 232.0 173.0 434% 28477 
Nicaragua 5667 4 69.7 237 3951 19.92 3.0 1.0 2.0 2.0 10% 329 
Niger 14704 21 83.1 3055 12219 68.66 0.3 0.3  0.3 0% 41 
Nigeria 151212 121 67.5 183397 102037 1052.97  0.0 1.0 0.5 0% 82 
Niue 2 0 49.0 0 1 0.00 N/A N/A N/A N/A N/A N/A 
Norway 4767 1 243.9 27 11626 56.58 145.0 134.0 139.0 139.3 246% 22936 
Oman 2785 2 41.8 51 1163 5.81 1.0 2.0 2.0 1.7 29% 274 
Pakistan 176952 2 53.4 3564 94518 470.18 1.0 5.0 10.0 5.3 1% 878 
Palau 20 0 60.8 0 12 0.06 0.3 0.3 0.3 0.3 421% 41 
Panama 3399 26 80.1 881 2724 15.91 2.0 3.0 2.0 2.3 15% 384 
Papua New Guinea 6577 10 48.7 673 3202 17.60 7.0 3.0  5.0 28% 823 
Paraguay 6238 9 85.7 570 5344 27.70 1.0 1.0 0.3 0.8 3% 123 
Peru 28837 15 113.5 4316 32727 172.16 0.0 14.0 26.0 13.3 8% 2195 
Philippines 90348 0 55.2 71 49843 242.45 20.0 15.0  17.5 7% 2881 
Poland 38104 0 253.7 144 96658 470.20 201.0 218.0 247.0 222.0 47% 36543 
Portugal 10677 7 233.5 759 24928 123.46 407.0 550.0 88.0 348.3 282% 57339 
Qatar 1281 4 14.3 46 183 1.03 0.3 1.0 1.0 0.8 73% 123 
Republic of Korea 48152 0 174.3 88 83906 408.05 113.0 55.0 122.0 96.7 24% 15912 
Republic of Moldova 3633 1 152.8 27 5552 27.07 4.0 4.0 3.0 3.7 14% 604 
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Romania 21361 1 201.6 250 43065 210.06 2.0 10.0 32.0 14.7 7% 2414 
Russian Federation 141394 9 194.5 12251 275079 1374.10 48.0 66.0 62.0 58.7 4% 9657 
Rwanda 9721 223 56.8 21650 5524 92.61 0.3 0.0 0.3 0.2 0% 27 
Saint Kitts and Nevis 51 5 103.1 3 53 0.26 N/A N/A N/A N/A N/A N/A 
Saint Lucia 170 4 113.3 7 193 0.96 0.3 0.3 0.3 0.3 26% 41 
Saint Vincent and the 
Grenadines 
109 45 113.5 49 124 0.75 0.3 0.3 0.3 0.3 33% 41 
Samoa 179 0 59.0 0 106 0.51 0.3 0.3 0.3 0.3 49% 41 
San Marino 31 0 278.1 0 86 0.42 N/A N/A N/A N/A N/A N/A 
Sao Tome and Principe 160 1 70.7 1 113 0.55 0.3 0.0  0.1 23% 21 
Saudi Arabia 25201 0 46.9 81 11809 57.64 11.0 13.0 15.0 13.0 23% 2140 
Senegal 12211 12 81.1 1405 9904 52.40 0.0 1.0  0.5 1% 82 
Serbia and Montenegro 9839 1 235.2 60 23145 112.67 1.0 2.0 7.0 3.3 3% 549 
Seychelles 84 6 104.9 5 88 0.44 0.3 0.3 0.3 0.3 56% 41 
Sierra Leone 5560 54 90.4 3000 5028 33.55  0.3  0.3 1% 41 
Singapore 4615 2 120.6 70 5566 27.27 8.0 5.0 5.0 6.0 22% 988 
Slovakia 5400 0 219.2 3 11837 57.54 99.0 12.0 0.0 37.0 64% 6091 
Slovenia 2015 0 272.5 2 5490 26.69 38.0 53.0 55.0 48.7 182% 8011 
Solomon Islands 511 0 35.9 1 183 0.89     0% 0 
Somalia 8926 14 77.2 1284 6888 37.37 N/A N/A N/A N/A N/A N/A 
South Africa 49668 631 90.9 313575 45161 1171.96 92.0 147.0 507.0 248.7 21% 40933 
Spain 44486 4 234.7 1753 104420 512.81 181.0 122.0 327.0 210.0 41% 34568 
Sri Lanka 20061 1 100.5 117 20165 98.36 8.0 9.0 14.0 10.3 11% 1701 
Sudan 41348 61 67.2 25281 27768 211.74 1.0 0.3  0.6 0% 103 
Suriname 515 32 83.6 165 430 2.59 0.3 0.3 0.3 0.3 10% 41 
Swaziland 1168 798 54.6 9326 637 31.42     0% 0 
Sweden 9205 0 228.1 28 20998 102.13 221.0 172.0 219.0 204.0 200% 33580 
Switzerland 7541 2 221.2 134 16683 81.49 229.0 273.0 263.0 255.0 313% 41975 
Syrian Arab Republic 21227 0 27.9 4 5914 28.75 1.0 0.3 2.0 1.1 4% 178 
Tajikistan 6836 2 37.3 109 2552 12.73 0.0 0.3  0.1 1% 21 
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Thailand 67386 92 132.0 62146 88942 621.03 49.0 49.0 55.0 51.0 8% 8395 
The former Yugoslav 
Republic of Macedonia 
2041 0 179.0 5 3654 17.77 0.3 0.3 0.0 0.2 1% 27 
Timor-Leste 1098 1 40.7 8 447 2.20 N/A N/A N/A N/A N/A N/A 
Togo 6459 133 62.0 8596 4003 45.57 0.3 0.3 0.3 0.3 1% 41 
Tonga 104 0 58.1 0 60 0.29 0.3 0.3 0.3 0.3 85% 41 
Trinidad and Tobago 1333 50 104.8 667 1397 8.82  2.0 2.0 2.0 23% 329 
Tunisia 10169 1 43.4 145 4411 21.88 19.0 20.0 22.0 20.3 93% 3347 
Turkey 73914 0 80.8 115 59699 290.49 2.0 13.0 5.0 6.7 2% 1097 
Turkmenistan 5044 1 60.0 53 3028 14.88 0.3 1.0 1.0 0.8 5% 123 
Tuvalu 10 0 91.0 0 9 0.04     0% 0 
Uganda 31657 335 49.4 106137 15652 398.46 9.0  45.0 27.0 7% 4444 
Ukraine 45992 22 192.3 10081 88443 460.45 84.0   84.0 18% 13827 
United Arab Emirates 4485 2 16.1 68 724 3.73 2.0 2.0 3.0 2.3 63% 384 
United Kingdom 61231 0 266.5 212 163157 793.59 1861.0 1437.0 2275.0 1857.7 234% 305789 
United Republic of 
Tanzania 
42484 310 63.0 131585 26774 529.81 0.0 0.0 0.0 0.0 0% 0 
United States of America 311666 5 193.7 14050 603770 2977.00 17355.0 23005.0 20550.
0 
20303.
3 
682% 3342112 
Uruguay 3349 5 238.2 179 7977 39.31 0.0 0.0 16.0 5.3 14% 878 
Uzbekistan 27191 0 42.6 75 11576 56.49 3.0 3.0 3.0 3.0 5% 494 
Vanuatu 234 0 48.2 0 113 0.55 0.3 0.3  0.3 46% 41 
Venezuela 28121 5 68.6 1530 19278 98.34 2.0 6.0 11.0 6.3 6% 1043 
Viet Nam 87096 15 79.4 12670 69132 374.46 13.0 16.0 19.0 16.0 4% 2634 
Yemen 22917 1 49.5 176 11352 55.70 0.3 0.3 0.3 0.3 0% 41 
Zambia 12620 666 58.6 83990 7393 291.05 1.0 0.3 1.0 0.8 0% 123 
Zimbabwe 12463 1463 66.9 182378 8342 594.52  5.0  5.0 1% 823 
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HUMAN RIGHTS WATCH
350 Fifth Avenue, 34th Floor
New York, NY 10118-3299
www.hrw.org
H U M A N  
R I G H T S  
W A T C H
Community health worker Mary Njoki speaks to
a mother of twins during a home-based care
visit on March 6, 2010, in Mathare, a slum in
Nairobi. Njoki taught the twins’ mother how to
apply a medicine for their skin condition but
has not been trained to assess pain and has
no access to pain medicines. 
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Global State of Pain Treatment
Access to Palliative Care as a Human Right
Every year, tens of millions of people around the world suffer severe pain and other debilitating symptoms caused
by illnesses like cancer and HIV/AIDS. Human Rights Watch interviews in several countries have documented
suffering so intense that patients would often rather die than live with their pain.
Almost all this suffering is unnecessary because pain medicines are safe, cheap, and effective and low-cost
palliative care services could address severely ill patients’ physical, psychological, and social needs.
Yet in most countries availability of strong pain medicines is almost nonexistent and palliative care is a neglected
health service. This violates the right to the highest attainable standard of health.
This report uses publicly available data on the consumption of pain medicines to illustrate the enormous extent
of unmet need for pain treatment. It also presents the results of a survey of healthcare workers in 40 countries
regarding the main barriers to better pain treatment and palliative care.      
Global State of Pain Treatment calls upon governments to assess the need for pain treatment and palliative care
in their own countries and to systematically identify and address barriers to access, in accordance with their
obligations under international law. International organizations such as the World Health Organization and the
United Nations drug control agencies should assist countries in their efforts to end unnecessary suffering from
pain. 
